T he discovery of streptomycin, a natural antibiotic produced by Streptomyces griseus, marked the beginning of two formative disciplines within the field of infectious diseases-namely, the study of bacterialderived (rather than fungal-or plant-derived) medicinal compounds and the drug treatment of tuberculosis (TB) (1) . This achievement initiated decades of research in the discovery and use of anti-TB drugs, ultimately leading to the development of the 6-month, multidrug regimen currently used for the cure of drug-susceptible TB (2) . Unfortunately, failures in the implementation of this curative regimen, which are partly due to the challenges of its complex and lengthy nature, have led to the development and transmission of drugresistant strains of Mycobacterium tuberculosis. Today, TB remains an enormous global health burden, causing an estimated 1.3 million deaths and 8.7 million new cases in 2012, and a growing percentage of TB (more than 30% of new cases in some countries) is multidrug-resistant (3). Thus, new drugs addressing novel M. tuberculosis targets are needed to provide different therapy options for patients with drug-resistant TB and also to both shorten and simplify treatment of drugsensitive TB. Ideally, these new drugs should be combined in regimens tackling both drugsensitive and drug-resistant TB, representing a paradigm shift toward more universally useful TB treatment regimens.
Bacterial-derived natural products remain a rich source for antibacterial lead compounds. In fact,~80% of the currently used antibiotics are either directly derived from bacterial metabolic pathways or represent structural derivatives of metabolites with improved pharmaceutical properties (4) . However, due to the reduced interest in development of antibacterial drugs in the last decades of the 20th century, quite a number of promising natural product leads were not advanced to clinical development. Recently, natural product and antibiotic research has been revitalized, not only because of the urgent need to identify novel antibiotics but also owing to advanced technologies becoming available. Thus, researchers are now enabled to overcome hurdles in natural product research, such as target identification by deciphering the self-resistance mechanisms in producer strains through whole-genome sequencing and compound optimization by genetic engineering. Successful recent applications of these capabilities include the derivation of semisynthetic spectinamides found to be highly active against both drug-resistant and -susceptible M. tuberculosis strains (5) and the identification of InhA as the mycobacterial target of the Dactylosporangium fulvum-produced pyridomycin (6) .
In a search for neglected antibiotics with high anti-TB potential, Sanofi reinvestigated griselimycin (GM) (Fig. 1) , a cyclic peptide that was isolated from two strains of Streptomyces identified in the 1960s (7) . GM was found to have antibacterial activity specifically against organisms within the Corynebacterineae suborder, notably including Mycobacterium species, which prompted the company Rhône-Poulenc to pursue development of GM as an anti-TB drug. The first human studies were promising but revealed poor pharmacokinetics of GM, in particular short plasma elimination half-life after oral administration (8, 9) . Following elucidation of the compound's structure (10, 11) , a derivatization program was initiated to find GM analogs with improved pharmacokinetic properties (12, 13) ; however, this program was terminated in the 1970s after rifampin (RIF) became available for TB treatment. Because of earlier reports of the effectiveness of GM against drug-resistant M. tuberculosis (14, 15) , we recently reinitiated studies on this natural product lead with the ultimate goal of introducing a highly active, stable, and safe derivative of this compound class into the TB drug development pipeline.
Development of GM analogs
Our primary optimization goals for GM were to increase its potency, metabolic stability, and exposure. Metabolic stability profiling of natural, less abundant analogs of GM identified Pro 8 as a main site of metabolic degradation, supported by the finding that the methyl derivative [methylgriselimycin (MGM)] (Fig. 1 ) was markedly more stable than GM itself after incubation with human liver microsomes (Table 1) . Because only very small amounts of MGM are produced naturally, a total synthesis route was elaborated to provide access to MGM and related analogs (see supplementary text). Structure-activity relationships of new synthetic GM analogs resulting from this approach confirmed that incorporation of substituents at Pro 8 led to metabolically highly stable compounds and also indicated that increasing lipophilicity considerably increased in vivo exposure in plasma and lungs of mice, as well as in vitro activity against M. tuberculosis (see supplementary text). From these efforts, cyclohexylgriselimycin (CGM) (Fig. 1 ) was identified. The minimum inhibitory concentration (MIC) values of CGM were 0.06 and 0.2 mg/ml for the drugsusceptible M. tuberculosis strain H37Rv in broth culture and within macrophage-like (RAW264.7) cells, respectively (Table 1) . CGM exhibited timedependent bactericidal activity in vitro ( Fig. 2A) . Although the unbound fraction of CGM in plasma was low (0.3 and 0.4% in human and mouse plasma, respectively), the MIC shift of CGM in the presence of human or mouse sera was only
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Research articles SCIENCE sciencemag.org around five-or sevenfold, respectively ( Table 1) . The MIC values of CGM were similar for a range of M. tuberculosis strains from different lineages (representing geographical and evolutionary diversity), as well as for strains monoresistant to first-or second-line anti-TB drugs (table S1) , demonstrating a lack of cross-resistance. GM, MGM, and CGM were not active against M. tuberculosis under hypoxic conditions in which the bacteria were not actively multiplying (Table 1) . CGM exhibited optimized adsorption, distribution, metabolism, and excretion properties; that is, high oral bioavailability (89%), moderate total plasma clearance (1.1 liter/hour per kilogram), and a large volume of distribution (5.5 liter/kg). Exposure and half-life in mice (supportive of once-daily dosing) were higher than for GM and MGM. In addition, over the 30-to 100-mg/kg dose range, CGM exposure in plasma and lung increased roughly with dose proportionality and continued to increase over the 100-to 600-mg/kg dose range (table S2) . Moreover, CGM exhibited limited potential for drug-drug interactions, as neither CYP induction nor inhibition was observed, and the contribution of CYP to degradation was balanced, indicating that induction of CYPs by other drugs should not affect CGM exposures (Table 1) . CGM (at concentrations up to 5000 mg/ml) did not increase the number of revertant colonies in Ames II testing with TA98 and mixed strains of Salmonella typhimurium, indicating a lack of mutagenicity. Additionally, no chromosomal aberrations were observed in CGM-exposed mammalian cells, as tested with L5178Y cells (at CGM concentrations up to 1000 mg/ml, with or without metabolic activation) and with CHO-K1 cells ( fig. S1 ), indicating a lack of genotoxicity.
CGM activity in mouse models of TB
To assess the in vivo activity of CGM, we conducted dose-ranging experiments using mouse models of acute and chronic TB (see supplementary materials and methods). In the acute model, which is used to test the antimicrobial activity of compounds and regimens against bacteria actively multiplying in vivo, mice were aerosol-infected with M. tuberculosis, and oral administration of CGM (at daily doses ranging from 10 to 600 mg/kg) was initiated on the day after infection. After 4 weeks, all of the untreated control mice had died, whereas all of the mice treated with any dose of CGM survived. As expected, mice treated with isoniazid (INH) at 10 mg/kg experienced a decrease of~3 log 10 colony-forming units (CFUs) in the lungs, whereas mice receiving RIF at 10 mg/kg, which is expected to have poor initial activity in this model (16) , did not die but did experience bacterial growth in the lungs (Fig. 2B) . In mice receiving 10 and 25 mg/kg of CGM, neither the development of gross lung lesions ( fig. S2 ) nor bacterial growth could be prevented (Fig. 2B ). Total prevention of bacterial growth and gross lung lesions occurred in mice treated with 50 mg/kg, defining the minimal effective dose of CGM. The CFU count decreased by~2 log 10 in the lungs compared with the CFU count at initiation of treatment with a daily 100-mg/kg dose, defining the minimal bactericidal dose. In mice treated with 200-, 400-, and 600-mg/kg doses, a dose-dependent decline in lung CFU counts was observed (P < 0.0001), and the lungs of mice receiving the 600-mg/kg daily dose were culture-negative after 4 weeks of treatment. In the chronic model, which is used to test for antimicrobial activity against a stable bacterial population in vivo, mice were aerosol-infected, achieving a low implantation of 2.21 log 10 CFU per lung, and treatment was initiated 4 weeks later when a stable, host-contained infection was established at nearly 7 log 10 CFU per lung. After 4 weeks of treatment, all doses of CGM exhibited some degree of activity, with doses of 50 mg/kg and higher resulting in statistically significant differences in lung CFU counts from the untreated control (P ≤ 0.01) (Fig. 2C and  fig. S2 ). Treatment with CGM at 100 mg/kg resulted in a decrease in lung CFU counts similar to that observed with RIF at 10 mg/kg. In both SCIENCE sciencemag.org 5 JUNE 2015 • VOL 348 ISSUE 6239 1107 Table 1 . Optimization parameters for GM and derivatives. C max , maximum concentration; AUC, area under the concentration curve; V ss , volume of distribution; t ½ , half-life; nd, not determined. Pharmacokinetic parameters (C max , AUC, and t ½ ) were determined after a single oral administration of 30 mg/kg of the test compound in mice. For oral bioavailability, a single oral dose was compared to a single intravenous dose of 3 mg/kg. F = [AUC oral ]/[AUC iv ], the ratio of exposure of an equivalent dose after nonintravenous (in this case, oral) and intravenous administration as a measure of bioavailability.
Optimization parameter Compound

GM MGM CGM
MIC (mg/ml) for M. tuberculosis in liquid culture 1 0.6 0.06 MIC (mg/ml) for M. tuberculosis in liquid culture containing 25% human serum of these experiments, no overt adverse effects of CGM administration were observed in treated mice.
Due to the promising bactericidal activity of CGM when administered as monotherapy, we evaluated the activity of this compound when administered together with first-line anti-TB drugs in the mouse model of TB chemotherapy. Standard TB treatment comprises a 2-month intensive phase of daily RIF, INH, pyrazinamide (PZA), and ethambutol, followed by a 4-month continuation phase of daily RIF and INH. We designed an experiment to assess the bactericidal activity of CGM (at the minimal bactericidal dose of 100 mg/kg per day) used alone and in combination during the first 3 months of treatment. Mice were aerosolinfected with M. tuberculosis (implantation of 3.26 log 10 CFU per lung), and treatment was initiated 2 weeks after infection, when the lung CFU count had reached 7.43 log 10 . In these experimental conditions, CGM alone was as active as INH (the most bactericidal first-line drug), reducing CFU counts in the lungs of mice by 3.78 log 10 over 3 months, indicating that on a molar basis, CGM (1196 g/mol) had equivalent potency to INH (137 g/mol). However, at any time point, the combination of INH and CGM was as active as either INH or CGM alone. The combination of CGM with PZA was as active as the standard combination of INH, RIF, and PZA, reducing lung CFU counts in the mice by 5.5 log 10 over 3 months (table S3) . Additionally, the combination of CGM with RIF was much more active than the standard combination (additional 2 log 10 CFU decline), nearly resulting in mouse lung culture conversion by week 12 of treatment. Even more impressive was the activity of the three-drug combination of RIF, PZA, and CGM that resulted in mouse lung culture conversion after only 8 weeks of treatment, representing killing of >7 log 10 CFU in the lungs. In contrast and as expected, in the mice receiving the standard drug combination, lung CFU counts declined by~4.4 and~5.7 log 10 by weeks 8 and 12, respectively ( Fig. 2D and table S3 ). To assess the activity of CGM (at 100 mg/kg per day) during the continuation phase, mice received the standard regimen for the first 8 weeks of treatment, and then CGM was administered alone or in combination during weeks 8 to 20. The bacterial population remaining during the continuation phase had survived the initial 8 weeks of treatment and may have been enriched for organisms that are phenotypically tolerant to the antibiotics (i.e., the so-called "persisters"). The replacement of either of the drugs in the standard continuation regimen (RIF and INH) with CGM did not affect the time to mouse lung culture conversion (20 weeks) , and no statistically significant differences were observed in lung CFU counts between these groups at any time point (table S4) . The bactericidal activity of the combination of INH with CGM was not significantly different from that of CGM alone at any time point. However, 
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Due to the promising bactericidal activity of CGM when administered as monotherapy, we evaluated the activity of this compound when administered together with first-line anti-TB drugs in the mouse model of TB chemotherapy. Standard TB treatment comprises a 2-month intensive phase of daily RIF, INH, pyrazinamide (PZA), and ethambutol, followed by a 4-month continuation phase of daily RIF and INH. We designed an experiment to assess the bactericidal activity of CGM (at the minimal bactericidal dose of 100 mg/kg per day) used alone and in combination during the first 3 months of treatment. Mice were aerosolinfected with M. tuberculosis (implantation of 3.26 log 10 CFU per lung), and treatment was initiated 2 weeks after infection, when the lung CFU count had reached 7.43 log 10 . In these experimental conditions, CGM alone was as active as INH (the most bactericidal first-line drug), reducing CFU counts in the lungs of mice by 3.78 log 10 over 3 months, indicating that on a molar basis, CGM (1196 g/mol) had equivalent potency to INH (137 g/mol). However, at any time point, the combination of INH and CGM was as active as either INH or CGM alone. The combination of CGM with PZA was as active as the standard combination of INH, RIF, and PZA, reducing lung CFU counts in the mice by 5.5 log 10 over 3 months (table S3) . Additionally, the combination of CGM with RIF was much more active than the standard combination (additional 2 log 10 CFU decline), nearly resulting in mouse lung culture conversion by week 12 of treatment. Even more impressive was the activity of the three-drug combination of RIF, PZA, and CGM that resulted in mouse lung culture conversion after only 8 weeks of treatment, representing killing of >7 log 10 CFU in the lungs. In contrast and as expected, in the mice receiving the standard drug combination, lung CFU counts declined by~4.4 and~5.7 log 10 by weeks 8 and 12, respectively ( Fig. 2D and table S3 ). To assess the activity of CGM (at 100 mg/kg per day) during the continuation phase, mice received the standard regimen for the first 8 weeks of treatment, and then CGM was administered alone or in combination during weeks 8 to 20. The bacterial population remaining during the continuation phase had survived the initial 8 weeks of treatment and may have been enriched for organisms that are phenotypically tolerant to the antibiotics (i.e., the so-called "persisters"). The replacement of either of the drugs in the standard continuation regimen (RIF and INH) with CGM did not affect the time to mouse lung culture conversion (20 weeks) , and no statistically significant differences were observed in lung CFU counts between these groups at any time point (table S4) . The bactericidal activity of the combination of INH with CGM was not significantly different from that of CGM alone at any time point. However, this combination was significantly more bactericidal than INH alone after 16 (P ≤ 0.05) and 20 (P ≤ 0.0001) weeks of treatment, with the effect being additive. Thus, taken together, our data indicate that CGM is highly active against actively replicating M. tuberculosis, both in vitro and in vivo, and also exhibits bactericidal activity against nonreplicating bacteria in vivo.
Self-resistance to GM in Streptomyces
The demonstrated activity of CGM against both drug-susceptible and -resistant M. tuberculosis (14, 15) and the notable enhancement of the bactericidal activity of the standard TB drug regimen with the addition of CGM in mice suggested that the mechanism of action of CGM may be different from other anti-TB drugs. GM and MGM are naturally produced by some species of Streptomyces, and we identified the biosynthetic gene cluster responsible for GM and MGM production in S. sp. DSM-40835 (17), a strain naturally resistant to GM, and examined it for the presence of a possible resistance-conferring component. We found a homolog of the dnaN gene, which encodes the sliding clamp (also called the b clamp) of DNA polymerase, within the nonribosomal peptide megasynthetase cassette for GM synthesis ( fig. S3A and table S5 ). This dnaN homolog, annotated as griR, encoded a protein with 51% identity to DnaN from the same strain ( fig. S3 , B and C). To examine the effect of GriR on susceptibility to GM, we introduced the gene into Streptomyces coelicolor A3(2), a strain susceptible to this natural product (and naturally lacking the entire GM biosynthesis cassette) (18) . The presence of the griR-expressing plasmid allowed the strain to survive in the presence of GM ( fig. S3D and table S6), suggesting that overexpression of griR mediated GM resistance. Comparison of the DnaN sequence from different  microbial species revealed a clear cluster break  between GM-sensitive and -resistant bacteria based  on homology of the sliding clamp (fig. S3C and  table S6 ). Taken together, these data suggest that GM and its derivatives target DnaN and may thus interfere with DNA replication.
GM resistance in mycobacteria
The intriguing relationship between dnaN sequence, copy number of the gene, and resistance to GM observed in Streptomyces compelled us to examine the mechanism(s) of resistance to this compound in mycobacteria. Using the fast-growing, nonpathogenic, and GM-sensitive (MIC: 4.5 mg/ml) M. smegmatis, we selected GM-resistant bacteria in vitro. The GM-resistant M. smegmatis (which occurred at an extremely low frequency; at a GM concentration of 10 mg/ml the frequency was 5 × 10
) exhibited an altered, elongated cellular morphology (Fig. 3A) , as has been previously observed in GM-exposed M. tuberculosis (9) . The GM-resistant bacteria were cross-resistant to MGM and CGM, but not to RIF or any other tested antibiotic (table S7) . Genome sequence comparisons between the wild-type (WT) parent strain and mutants generated via stepwise exposure to increasing concentrations of GM (up to 40 mg/ml) revealed amplification of a chromosomal segment containing dnaN, with a single point mutation in the Pribnow box of the promoter region (115 G > A) (19) (tables S8 and S9), suggesting that mycobacterial resistance to GM, like that of Streptomyces, is mediated by amplification of DnaN. A number of inconsistent single-nucleotide polymorphisms (SNPs) were also observed. All mutants analyzed contained head-to-tail repeats of a chromosomal segment, but these segments or amplicons varied in size (ranging from 12 to 28 kb in length) and copy number (ranging from 3 to 49 copies), and occurrence of the amplicons was observed at different steps in the selection process (Fig. 3B, fig S4, and table S8 ). In addition to dnaN and its promoter, the amplicons contained dnaA, recF, gyrB, and up to more than 20 additional genes (table S9) ; they also all included the ori site. Amplification of a chromosomal segment was confirmed by Southern blot (Fig. 3, C  and D) . Based on the high copy number of the amplicons that include the ori site, formation of an extrachromosomal element could not be ruled out. However, plasmids were not detected by either standard plasmid isolation methods or agarose gel analysis. Yet in both M. smegmatis and M. tuberculosis, plasmids containing the same ori as the chromosome are usually maintained at a relatively low copy number (20, 21) , and naturally occurring plasmids in mycobacteria are known to be difficult to isolate (22) .
Although the exact sequence of the amplicons varied among GM-resistant mutants, the 115 G > A transition mutation in the dnaN promoter occurred in all mutants at the 2.5-mg/ml GM exposure step, leading to an MIC upshift from the baseline 4 mg/ml to 8 to 16 mg/ml (table S8) . This point mutation was not consistently maintained in all steps of increasing GM concentration, being either replaced or complemented in mutants exposed to higher GM concentrations by amplification of a dnaN-containing chromosomal segment, which led to resistance up to or greater than 64 mg/ml. Resistance to GM was accompanied by considerable fitness costs, whereby M. smegmatis growth was negatively correlated with increasing levels of resistance ( fig. S5 ), in some cases growing so poorly that we could not determine MIC values (table S8) . Our data indicate that when GM is removed from the growth media, these genetic and phenotypic modifications begin to be reversed, including a decrease in amplicon copy number, a downshift in MIC, and less growth retardation ( fig. S5 and table S8 ).
The unprecedented mechanism of gaining resistance to GM in our in vitro experiments with M. smegmatis prompted us to determine the relevance of these findings during in vivo infection with M. tuberculosis. To select resistant bacteria in vivo, nude mice were aerosol-infected with the fully drug-susceptible M. tuberculosis strain H37Rv and then treated by monotherapy with either INH (5 mg/kg) or CGM (100 mg/kg). Without the pressure from a functional immune system, monotherapy (when administered once daily, 5 days per week) with even the most bactericidal drug (INH) cannot prevent bacterial multiplication in these mice when drug levels in the blood fall below the therapeutic concentration, which, based on the half-life of INH (~1.5 hours) (23) and CGM (~4 hours) (Table 1 ) in the mouse, should occur daily and over the weekends. As anticipated, after 4 weeks of treatment, the lung bacterial loads began to increase in mice receiving either INH or CGM ( fig. S6A ). CFUs isolated from the CGM-treated mice were more than 10 times less sensitive to CGM (MIC: 1 to 2 mg/ml) (see proportion of CFUs growing on CGM-containing agar plates in table S10). Using the agar proportion method, the CGM-resistant M. tuberculosis were found to be fully susceptible to INH and RIF, as well as moxifloxacin and streptomycin. Genomic analysis of CGM-resistant colonies revealed an amplification of a 10.3-kb chromosomal segment containing the dnaN gene, together with four other genes and the ori site (fig. S6B and table  S11) , which was present in the CGM-resistant M. tuberculosis but absent in the WT parent strain. No SNPs were observed in the CGM-resistant bacteria compared with the WT parent strain. Thus, the mechanism of resistance observed in vitro with M. smegmatis was also observed in vivo with M. tuberculosis.
Characterization and crystal structure analysis of the GM-DnaN interaction
To confirm our genomic-based findings that DnaN is the target of GM and its derivatives, we used surface plasmon resonance (SPR) to characterize the binding of GM, MGM, and CGM with DnaN from M. smegmatis, M. tuberculosis, and Esche- 
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[SD] To gain a better understanding of the molecular interactions responsible for GM-DnaN complex formation, cocrystal structures of GM and CGM bound to mycobacterial DnaN proteins were determined. The structures of M. smegmatis DnaN with GM and CGM were refined to resolutions of 2.1 and 2.3 Å, respectively, whereas the structures of the M. tuberculosis DnaN with bound GM and CGM were refined to resolutions of 2.2 and 1.9 Å, respectively (table S12). Both inhibitors were well defined in the electron density maps ( fig. S8 ). GM and CGM bound to a hydrophobic cleft between domains II and III of the sliding clamp (Fig. 4A) , which has been identified previously as the peptide interaction site responsible for the binding of DNA polymerases and other DNA-modifying enzymes (24, 25) ) for M. smegmatis (or M. tuberculosis) (Fig. 4B and fig.  S9 ). Subsite one of the peptide-binding pocket is occupied by the cyclic part of the ligand, whereas subsite two harbors the linear part of the GM molecule (Fig. 4C ). This linear section and the adjacent half of the macrocycle superimpose very well for GM and CGM, whereas differences are visible on the opposite side of the macrocycle (figs. S10 and S11A). The ligands seem to be less tightly bound in this area, thus exhibiting a higher degree of flexibility ( fig. S11B ). The additional cyclohexyl moiety of CGM protrudes into the solvent and is involved in the formation of crystal contacts (fig. S12) ; the crystal packing might induce the observed differences in CGM binding as compared with GM and thus may not be physiologically relevant.
Binding of GM to the peptide interaction site of DnaN should lead to inhibition of the DnaN interaction with the polymerase III a subunit (DnaE1). To test this, we used SPR to assess the effect of GM on the binding of DnaN with a DnaE1 peptide that contains the internal DnaN binding motif and is known to be essential for processive replication in E. coli (26) . Binding of this peptide decreased by half when the sliding clamp was saturated with GM ( fig. S13 ). Inhibition of DnaE1 binding to DnaN should result in inefficient replication with decreased processivity and may lead to DNA strand breaks. Induction of the SOS response was observed in GM-exposed M. smegmatis ( fig. S14 ).
Several functional and structural studies have indicated that the sliding clamp may be a feasible antibacterial target that can be addressed by small molecules and peptidic inhibitors (24, (27) (28) (29) . Although inhibition of DNA replication does not necessarily lead to immediate bacterial cell death, blocking the replication process may induce other lethal damage within the cell, such as induction of the SOS response ( fig. S14 ) and/or toxin-antitoxin-like stress, as in the case of the quinolones, which block DNA replication by targeting topoisomerases but kill bacteria rapidly (30) . In fact, DnaN was recently shown to be targeted by a toxin-antitoxin system in Caulobacter crescentus (31) . The cell-elongation phenotype of GM-exposed mycobacteria indicates that blocking DNA replication induces a wider cellular response; this cell-elongation effect has also been reported in M. fortuitum upon exposure to the fluoroquinolone ofloxacin (32) . Furthermore, in both Gram-positive and Gram-negative bacteria, the sliding clamp has been demonstrated to interact with DNA repair proteins, including many induced during the SOS response (33) . Thus, the interaction of GMs with DnaN could also affect DNA repair, contributing to the bactericidal activity of the compounds. Whereas previously reported DnaN binders inhibited bacterial growth with only moderate potency, GM and its derivatives represent the first DnaN inhibitors with picomolar affinity to the target and high efficacy (MIC values ≤1.0 mg/ml) against mycobacteria. Known small-molecule DnaN binders targeted the deep hydrophobic pocket of subsite one, whereas subsite two remained empty. Peptidic inhibitors and the natural interacting peptides target both subsites; the linear segment and part of the macrocycle of GM superimposed very well with their backbone, thereby mimicking the conformation of a linear peptide bound to DnaN ( fig. S15 ). The specific inhibition of mycobacteria by GM, which should leave commensal microbiota intact, constitutes an additional advantage with respect to the selection of resistance.
Conclusion
Total synthesis of new GMs led to the optimized CGM, which demonstrated a clear potential for TB treatment by targeting the DNA polymerase sliding clamp. Currently, CGM and a few other GM derivatives are being further profiled to select the best drug candidate to move forward in development, with CGM being one of the lead compounds pursued in late preclinical studies involving broad toxicity testing. In this work, we have demonstrated the validity of DnaN as a drug target and have identified direct small-moleculeDnaN interactions that probably interrupt essential polymerase and DNA repair activities in mycobacteria, leading to killing both in vitro and in vivo. Through the selection of GM-or CGMresistant bacteria, we discovered that resistance to these compounds is possible, albeit at a very sciencemag.org SCIENCE low frequency, and is mediated through multiplication of dnaN, whereby the resistance to GMs increases with increasing dnaN amplification. The nature of the amplicons, consisting of clonal repeats that differ slightly between bacterial isolates but all include the ori site, and the observed decrease in target amplification in the absence of GM suggest that the amplification is connected to severe fitness costs, as observed by the slow growth of the mutants. As exposure to GM triggered chromosomal duplications in a concentrationdependent manner in vitro, GM could possibly serve as a tool to study the mechanism of chromosomal duplication events in mycobacteria that have contributed to the natural variation between different lineages. Because there is no preexisting resistance to GMs due to the different mode of action compared with that of existing TB drugs, and because resistance occurs at an extremely low frequency and is associated with a severe fitness cost, this new series has the potential to contribute to drug regimens with utility for patients with both drug-sensitive and drug-resistant TB. In addition, our work has confirmed the sliding clamp as an antimicrobial target and revealed an unusual mechanism of conferring drug resistance that is applicable to the wider antibiotic discovery field. grants from Sanofi-Aventis (Amd. 14, grant 111937, and Amd. 7, grant 103671). We thank C. The manipulation of domains by external fields in ferroic materials is of major interest for applications. In multiferroics with strongly coupled magnetic and electric order, however, the magnetoelectric coupling on the level of the domains is largely unexplored. We investigated the field-induced domain dynamics of TbMnO 3 in the multiferroic ground state and across a first-order spin-flop transition. In spite of the discontinuous nature of this transition, the reorientation of the order parameters is deterministic and preserves the multiferroic domain pattern. Landau-Lifshitz-Gilbert simulations reveal that this behavior is intrinsic. Such magnetoelectric correlations in spin-driven ferroelectrics may lead to domain wall-based nanoelectronics devices.
T he entanglement of magnetic and electric long-range orders in magnetically induced ferroelectrics is a key to the manipulation of dielectric properties by magnetic fields and vice versa. Long believed to be a lowtemperature phenomenon, these strong magnetoelectric correlations are now gaining importance in the light of recent studies that report spindriven ferroelectricity in conditions approaching room temperature (1-3). The manipulation of domains by external fields in ferroic materials is of major interest for applications. In multiferroics with strongly coupled magnetic and electric order, however, the magnetoelectric coupling on the level of the domains is largely unexplored. We investigated the field-induced domain dynamics of TbMnO 3 in the multiferroic ground state and across a first-order spin-flop transition. In spite of the discontinuous nature of this transition, the reorientation of the order parameters is deterministic and preserves the multiferroic domain pattern. Landau-Lifshitz-Gilbert simulations reveal that this behavior is intrinsic. Such magnetoelectric correlations in spin-driven ferroelectrics may lead to domain wall-based nanoelectronics devices.
T he entanglement of magnetic and electric long-range orders in magnetically induced ferroelectrics is a key to the manipulation of dielectric properties by magnetic fields and vice versa. Long believed to be a lowtemperature phenomenon, these strong magnetoelectric correlations are now gaining importance in the light of recent studies that report spindriven ferroelectricity in conditions approaching room temperature (1-3). low frequency, and is mediated through multiplication of dnaN, whereby the resistance to GMs increases with increasing dnaN amplification. The nature of the amplicons, consisting of clonal repeats that differ slightly between bacterial isolates but all include the ori site, and the observed decrease in target amplification in the absence of GM suggest that the amplification is connected to severe fitness costs, as observed by the slow growth of the mutants. As exposure to GM triggered chromosomal duplications in a concentrationdependent manner in vitro, GM could possibly serve as a tool to study the mechanism of chromosomal duplication events in mycobacteria that have contributed to the natural variation between different lineages. Because there is no preexisting resistance to GMs due to the different mode of action compared with that of existing TB drugs, and because resistance occurs at an extremely low frequency and is associated with a severe fitness cost, this new series has the potential to contribute to drug regimens with utility for patients with both drug-sensitive and drug-resistant TB. In addition, our work has confirmed the sliding clamp as an antimicrobial target and revealed an unusual mechanism of conferring drug resistance that is applicable to the wider antibiotic discovery field. Ayato Iyama, 6 Nadir Aliouane, 7 Tsuyoshi Kimura, 6 Steven L. Johnson, 5 
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RESULTS
Generation of primate bispecific antiTfR/BACE1 antibody variants
Previously, anti-TfR A , an antibody that binds selectively to mouse TfR, was engineered to investigate the TfR pathway for brain uptake and safety liabilities in mice (6, 7) . We showed that by reducing affinity for TfR in either the bivalent or the monovalent (bispecific) format, brain uptake and biodistribution were improved. Here, we have now generated a new antibody to primate TfR, which cross-reacts with both human and monkey TfR expressed on human embryonic kidney (HEK) 293 cells (Fig. 1A) . This antibody was then humanized to generate anti-TfR 1C) . Consistent with its nonblocking properties, the anti-TfR 1 binding site was mapped to the apical domain, a site distant from these ligand binding sites (Fig. 1D ). To assess TfR affinity relationships for brain uptake, we generated a second lower-affinity variant called anti-TfR 2 by introducing a single alanine substitution into CDR-L3 (complementarity determining region L3) of the anti-TfR 1 light chain (Fig. 1E ). Monovalent TfR binding of anti-TfR 2 showed a 20-to 25-fold decrease in affinity to both human and monkey TfR (Fig. 1E ). Furthermore, there was an about fourfold decrease in monovalent binding affinity observed from human to monkey TfR for both anti-TfR variants, which is particularly relevant because previous studies have shown that modest changes in affinity can affect brain uptake (6, 8) .
Using "knob into holes" technology, a method that promotes heterodimerization of two different half-antibodies into a bispecific immunoglobulin G (IgG) antibody (9), primate cross-reactive anti-TfR variants were combined with an antibody directed against a target in the brain, β-secretase (BACE1), thus generating anti-TfR/BACE1 bispecific antibodies (Fig. 1E) . BACE1 is an aspartyl protease responsible for the first of two cleavage events in amyloid precursor protein (APP) that give rise to amyloid-β (Aβ) peptides, which accumulate as plaques in the brains of patients with Alzheimer's disease (10) . Although BACE1 is a therapeutic target for Alzheimer's disease, inhibition of BACE1 also provides an ideal pharmacodynamic (PD) signal for assessing the activity of antibodies that cross the BBB. To assess brain activity of the TfR bispecific antibody after systemic delivery in primates, we used a previously described anti-BACE1 antibody that binds to mouse, monkey, and human BACE1 (11) . As expected, both anti-TfR 1 /BACE1 and anti-TfR 2 /BACE1 were equally potent at reducing Aβ production in mouse neurons (Fig. 1F ).
Characterization of a human TfR knock-in mouse model
Brain uptake of the anti-TfR/BACE1 bispecific antibodies was first tested using a human TfR knock-in mouse, generated by introducing the human TFRC complementary DNA (cDNA) after exon 1 of the mouse Tfrc gene (fig. S1 ). To confirm TfR species specificity, we dosed wildtype and human TfR (TFRC) knock-in mice with control IgG, mouse-specific anti-TfR A , or primate-specific anti-TfR 1 . We observed anti-TfR antibody localization in the cortical vasculature of mouse brain 1 hour after dosing wild-type mice with mouse-specific antiTfR A only, whereas primate-specific anti-TfR 1 only stained human TfR knock-in mice ( Fig.  2A ). Brain antibody concentrations measured 1 day after dosing with anti-TfR/BACE1 (20 mg/kg) demonstrated brain uptake in a species-specific manner (Fig. 2B) . Enhanced TfR-dependent clearance was observed in both the hemizygous and homozygous human TfR knock-in mice when dosed with the primate-specific anti-TfR 1 /BACE1 ( fig. S1B ). This is likely a result of elevated human TfR protein expression across multiple tissues in both the hemizygous and homozygous mice ( fig. S1C ). We also noted that red blood cell counts and hemoglobin concentrations were altered between the wild-type and human TfR homozyogous mice but remained normal in hemizygous mice ( fig. S1D ). The hemizygous genotype was thus selected for subsequent dosing studies to best approximate wild-type TfR conditions.
Using therapeutic antibodies that need to cross the blood-brain barrier (BBB) to treat neurological disease is a difficult challenge. We have shown that bispecific antibodies with optimized binding to the transferrin receptor (TfR) that target β-secretase (BACE1) can cross the BBB and reduce brain amyloid-β (Aβ) in mice. Can TfR enhance antibody uptake in the primate brain? We describe two humanized TfR/BACE1 bispecific antibody variants. Using a human TfR knock-in mouse, we observed that anti-TfR/BACE1 antibodies could cross the BBB and reduce brain Aβ in a TfR affinity-dependent fashion. Intravenous dosing of monkeys with anti-TfR/BACE1 antibodies also reduced Aβ both in cerebral spinal fluid and in brain tissue, and the degree of reduction correlated with the brain concentration of anti-TfR/BACE1 antibody. These results demonstrate that the TfR bispecific antibody platform can robustly and safely deliver therapeutic antibody across the BBB in the primate brain. Florence Bordon-Pallier, 8 Mark Brönstrup, 3, 6 Gilles Courtemanche, 7 Martin Gerlitz, 6 Michel Geslin, 7 Peter Hammann, 9 Dirk W. Heinz, 2,3 Holger Hoffmann, 6 Sylvie Klieber, 10 Markus Kohlmann, 6 Michael Kurz, 6 Christine Lair, 7 Hans Matter, 6 Eric Nuermberger, T he discovery of streptomycin, a natural antibiotic produced by Streptomyces griseus, marked the beginning of two formative disciplines within the field of infectious diseases-namely, the study of bacterialderived (rather than fungal-or plant-derived) medicinal compounds and the drug treatment of tuberculosis (TB) (1). This achievement initiated decades of research in the discovery and use of anti-TB drugs, ultimately leading to the development of the 6-month, multidrug regimen currently used for the cure of drug-susceptible TB (2). Unfortunately, failures in the implementation of this curative regimen, which are partly due to the challenges of its complex and lengthy nature, have led to the development and transmission of drugresistant strains of Mycobacterium tuberculosis. Today, TB remains an enormous global health burden, causing an estimated 1.3 million deaths and 8.7 million new cases in 2012, and a growing percentage of TB (more than 30% of new cases in some countries) is multidrug-resistant (3). Thus, new drugs addressing novel M. tuberculosis targets are needed to provide different therapy options for patients with drug-resistant TB and also to both shorten and simplify treatment of drugsensitive TB. Ideally, these new drugs should be combined in regimens tackling both drugsensitive and drug-resistant TB, representing a paradigm shift toward more universally useful TB treatment regimens.
Bacterial-derived natural products remain a rich source for antibacterial lead compounds. In fact,~80% of the currently used antibiotics are either directly derived from bacterial metabolic pathways or represent structural derivatives of metabolites with improved pharmaceutical properties (4). However, due to the reduced interest in development of antibacterial drugs in the last decades of the 20th century, quite a number of promising natural product leads were not advanced to clinical development. Recently, natural product and antibiotic research has been revitalized, not only because of the urgent need to identify novel antibiotics but also owing to advanced technologies becoming available. Thus, researchers are now enabled to overcome hurdles in natural product research, such as target identification by deciphering the self-resistance mechanisms in producer strains through whole-genome sequencing and compound optimization by genetic engineering. Successful recent applications of these capabilities include the derivation of semisynthetic spectinamides found to be highly active against both drug-resistant and -susceptible M. tuberculosis strains (5) and the identification of InhA as the mycobacterial target of the Dactylosporangium fulvum-produced pyridomycin (6) .
In a search for neglected antibiotics with high anti-TB potential, Sanofi reinvestigated griselimycin (GM) (Fig. 1) , a cyclic peptide that was isolated from two strains of Streptomyces identified in the 1960s (7) . GM was found to have antibacterial activity specifically against organisms within the Corynebacterineae suborder, notably including Mycobacterium species, which prompted the company Rhône-Poulenc to pursue development of GM as an anti-TB drug. The first human studies were promising but revealed poor pharmacokinetics of GM, in particular short plasma elimination half-life after oral administration (8, 9) . Following elucidation of the compound's structure (10, 11), a derivatization program was initiated to find GM analogs with improved pharmacokinetic properties (12, 13) ; however, this program was terminated in the 1970s after rifampin (RIF) became available for TB treatment. Because of earlier reports of the effectiveness of GM against drug-resistant M. tuberculosis (14, 15), we recently reinitiated studies on this natural product lead with the ultimate goal of introducing a highly active, stable, and safe derivative of this compound class into the TB drug development pipeline.
Development of GM analogs
Our primary optimization goals for GM were to increase its potency, metabolic stability, and exposure. Metabolic stability profiling of natural, less abundant analogs of GM identified Pro 8 as a main site of metabolic degradation, supported by the finding that the methyl derivative [methylgriselimycin (MGM)] (Fig. 1 ) was markedly more stable than GM itself after incubation with human liver microsomes (Table 1) . Because only very small amounts of MGM are produced naturally, a total synthesis route was elaborated to provide access to MGM and related analogs (see supplementary text). Structure-activity relationships of new synthetic GM analogs resulting from this approach confirmed that incorporation of substituents at Pro 8 led to metabolically highly stable compounds and also indicated that increasing lipophilicity considerably increased in vivo exposure in plasma and lungs of mice, as well as in vitro activity against M. tuberculosis (see supplementary text). From these efforts, cyclohexylgriselimycin (CGM) (Fig. 1 ) was identified. The minimum inhibitory concentration (MIC) values of CGM were 0.06 and 0.2 mg/ml for the drugsusceptible M. tuberculosis strain H37Rv in broth culture and within macrophage-like (RAW264.7) cells, respectively (Table 1) . CGM exhibited timedependent bactericidal activity in vitro ( Fig. 2A) . Although the unbound fraction of CGM in plasma was low (0.3 and 0.4% in human and mouse plasma, respectively), the MIC shift of CGM in the presence of human or mouse sera was only (Fig. 2A) . Brain antibody concentrations measured 1 day after dosing with anti-TfR/BACE1 (20 mg/kg) demonstrated brain uptake in a species-specific manner (Fig. 2B) . Enhanced TfR-dependent clearance knock-in mice when dosed with the primate-specific anti-TfR 1 /BACE1 (fig. S1B ). This is likely a result of elevated human TfR protein expression across multiple tissues in both the hemizygous and homozygous mice 
Affinity-dependent brain uptake of anti-TfR/BACE1 variants in human TfR knock-in mice
We next assessed the brain uptake and activity of the anti-TfR/BACE1 bispecific antibody affinity variants in the hemizygous human TfR mice after a single 50 mg/kg intravenous dose.
We observed that the lower-affinity anti-TfR 2 / BACE1 antibody showed higher peripheral plasma and brain concentrations than did the anti-TfR 1 /BACE1 antibody (Fig. 2, C and  D) . Nevertheless, both bispecific antibodies reduced Aβ in the plasma and brain to the same extent at each assessed time point (Fig. 2 , E and F), suggesting that antibody concentrations exceeded the in vivo concentrations needed to drive Aβ reduction. This resulted in maximal BACE1 inhibition: maximum in vivo reduction of Aβ by anti-BACE1 antibody inhibition was ~55 to 65% based on allosteric and cellular mechanisms (11, 12) . Investigation of the impact of anti-TfR bispecific antibody dosing on brain TfR protein levels revealed an affinity-driven degradation of TfR, with only high-affinity anti-TfR 1 /BACE1 antibody significantly reducing TfR protein levels 1 day after dosing (Fig. 2G) . The affinity relationship with TfR degradation was recapitulated in vitro in both human (HEK293) and monkey (COS7) cells, where high-affinity monovalent anti-TfR 1 binding triggered TfR degradation (fig. S2, A and B) . This is a liability we have previously observed with highaffinity monovalent mouse TfR antibodies in vivo and limits brain uptake of TfR bispecific antibodies after multiple dosing (13) . These data demonstrate that the lower-affinity antiTfR 2 /BACE1 has more desirable therapeutic properties when dosed in the human TfR knock-in mouse model.
Brain uptake and activity of anti-TfR/ BACE1 antibody variants in nonhuman primates
Key steps in validating TfR as a viable pathway for therapeutic antibody delivery across the BBB include the demonstration of robust brain uptake and the assessment of initial safety risks after administration of TfR bispecific antibodies to primates. Cynomolgus monkeys were dosed intravenously with anti-TfR (Fig. 3A) . Both bispecific antibodies reduced peripheral plasma Aβ concentrations by greater than 50% (Fig. 3B) . Strikingly, the anti-TfR 1 /BACE1 antibody showed a robust and sustained reduction in Aβ concentrations in cerebrospinal fluid (CSF) (Fig. 3C) , a result that was corroborated by an equally robust reduction in the sAPPβ (soluble APPβ)/sAPPα ratio in CSF (Fig. 3D and fig. S3, A and B) , further verifying inhibition of BACE1.
We have previously shown in mouse that anti-TfR/BACE1 antibody substantially improves brain uptake and subsequent Aβ reduction relative to anti-BACE1 antibody (7). We thus conducted a similar comparison in nonhuman primates by measuring brain concentrations of the anti-TfR/BACE1 antibody variants, anti-BACE1 antibody, and control antibody from monkey brains harvested 1 day after a single 30 mg/kg intravenous dose. Directly correlating with Aβ and sAPPβ/sAPPα reductions in CSF (Fig. 3, C and D) , dosing with anti-TfR 1 /BACE1 antibody led to the highest concentration of bispecific antibody in all monkey brain regions assayed (Fig. 3E) . Furthermore, reductions in brain Aβ concentrations also correlated with reductions in CSF Aβ concentrations (Fig. 3F) ; however, the extent of Aβ reduction was more modest in brain relative to CSF, consistent with what has been reported (14) . Anti-TfR 2 /BACE1 antibody showed moderate brain uptake correlating with moderate reductions in CSF Aβ and sAPPβ/sAPPα ratio (compare Fig. 3E with Fig. 3, C and D) . The reduced affinity of anti-TfR 2 antibody for monkey TfR, relative to human TfR, explained the poorer brain uptake and relatively weaker CSF/brain PD effect seen in monkey compared to the human TfR knock-in mice. Compared to control antibody, anti-BACE1 antibody showed low brain uptake and no reduction in brain Aβ (Fig. 3, E and F) . The PK (pharmacokinetic)/ PD relationship shown in monkeys with anti-TfR/BACE1 illustrates the substantial improvement in brain uptake with the TfR bispecific antibody, providing evidence that TfR is a robust receptor-mediated pathway in the BBB of primates.
No reticulocyte loss with anti-TfR/ BACE1 in monkeys
In previous work, we reported that TfRpositive circulating reticulocytes in mice presented a major safety liability for anti-TfR antibodies, posing a significant concern for chronic dosing paradigms using an anti-TfR antibody platform (7) . Attenuating antibody effector function abolished acute clinical signs, although residual reticulocyte loss was still observed. Although primates have substantially fewer TfR-positive circulating reticulocytes in comparison to rodents, a critical assessment of the impact of our newly generated anti-TfR bispecific antibodies on the hematopoietic system in primates is warranted, with a particular focus on reticulocytes.
Time course analysis of reticulocytes, red blood cells, immature reticulocytes (which express the highest levels of TfR), hemoglobin, serum iron (Fe (Fig. 4, A and C) , impact on the hematopoietic system (Fig. 4, B and D) , or significant changes in serum iron concentrations (Fig.  4E) or TIBC (an indirect measure of circulating Tf concentrations) (Fig. 4F) . The lack of impact on hematological and iron-related blood parameters further confirmed the nonblocking nature of these primate-specific antiTfR bispecific antibodies in vivo (Fig. 1,B and  C) . Notably, both anti-TfR/BACE1 bispecific antibodies tested in these studies lacked Fcg receptor binding; thus, the possibility remains that anti-TfR antibodies with normal effector function could deplete TfR-positive cells that reside in bone marrow, as was previously shown in mice (7).
As we had seen robust TfR degradation with the high-affinity anti-TfR 1 /BACE1 antibody in the human TfR knock-in mice, we also assayed TfR protein levels in monkey brain after anti-TfR/BACE1 antibody dosing. Western blot analysis of brain TfR protein 1 day after dosing in monkeys did not show changes in TfR protein levels with either antiTfR/BACE1 bispecific antibody ( fig. S2C ).
DISCUSSION
Utilization of molecular "lifts" to cross the BBB has been experimentally investigated for several decades (1-3) ; however, success in translating these findings to humans remains elusive. One of the most studied BBB receptors, TfR, has shown promise in rodents but has not been assayed in primates. Furthermore, safety findings in mice that raise concerns about using TfR to enable large therapeutics such as antibodies to cross the BBB have recently been described (7). To determine if TfR is a viable target for drug delivery in humans, we generated several primate binding anti-TfR/BACE1 bispecific antibody variants. We tested these anti-TfR/ BACE1 antibodies both in a newly generated human TfR knock-in mouse model and in monkeys. The data we obtained, including no acute safety observations or reticulocyte loss in monkeys, suggest that TfR is indeed a viable target for drug delivery across the BBB in nonhuman primates and is worthy of further drug development.
Comparison of these data from the primatespecific anti-TfR/BACE1 antibodies in human TfR knock-in mice and monkeys revealed an optimal anti-TfR affinity that is neither too high nor too low. These results add critical insight into previous studies using mouse-specific anti-TfR antibodies (6, 7, 13) , thus identifying a cross-species principle that is likely to be intrinsic to the biology of the TfR pathway at the BBB. We propose a model (Fig. 5 ) in which brain uptake of anti-TfR-based antibody therapeutics is based on identifying the optimal affinity of the antibody for TfR. The data used to generate this model are based on single-arm (monovalent) binding to TfR, because previous work with bivalent antibodies only reflects the high-affinity context based on avidity from both antibody arms binding to TfR (6) . We have shown that high-affinity monovalent binding to TfR drives rapid antibody clearance and TfR degradation, thus limiting sustained brain exposure to antibody. In contrast, very low affinity binding to TfR results in substantially better peripheral blood antibody exposure as a result of reduced target-mediated clearance; however, maximal brain uptake is also reduced because of the extremely low affinity of antibody for TfR. Ultimately, the identification of an optimal affinity for TfR leads to sustained brain concentrations of antibody above a therapeutic threshold that is dependent on the potency SCIENCE sciencemag.org /BACE1 (triangle), or anti-BACE1 (inverted triangle). Statistical tests: one-way ANOVA (E and F) with Bonferroni multiple comparisons test compared to control IgG-dosed animals. *P < 0.05, ***P < 0.001, and ****P < 0.0001.
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SPReading the word: The importance of binding kinetics sciencemag.org SCIENCE primate binding anti-TfR/BACE1 bispecific antibody variants. We tested these anti-TfR/BACE1 antibodies both in a newly generated human TfR knock-in mouse model and in monkeys. The data we obtained, including no acute safety observations or reticulocyte loss in monkeys, TfR antibodies (6, 7, 13), thus identifying a cross-species principle that is likely to be intrinsic to the biology of the TfR pathway at the BBB. We propose a model (Fig. 5 ) in which brain uptake of anti-TfR-based antibody therapeutics is based on identifying the optimal affinity of the of the therapeutic arm (for example, BACE1). The exact optimal affinity may vary from species to species and from central nervous system target to target. A key difference in TfR biology between rodents and primates was functionally tested in this study, namely, the determination of reticulocyte loss after dosing with antiTfR antibody. We have shown previously that circulating reticulocytes in mice have substantially higher TfR protein expression than those of primates (7) . The finding that neither anti-TfR/BACE1 antibody variant caused reticulocyte loss in monkeys confirms this difference functionally (Fig. 4) and raises an important consideration: that TfR biology is not completely conserved between species. We propose that one reason moderate-affinity anti-TfR 1 /BACE1 antibody performs better in monkeys relative to the human TfR knock-in mouse is because of the about fourfold shift in affinity between antibody binding to human and monkey TfR. However, an equally important consideration is that the differences in biology between species may also lead to significantly different outcomes (for example, reticulocyte loss). These differences may include TfR expression, BBB physiology, and/ or antibody kinetics. As such, it is important to note that whereas rodent models may be very useful in identifying and providing the initial validation of BBB targets, the development of clinical candidates will require extensive investigation in nonhuman primates, including repeat-dosing studies to establish long-term safety and activity. In conclusion, these data illustrate the promise of targeting TfR as a potentially safe and robust target to boost antibody uptake in primate brain, laying the foundation for future testing in humans.
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MATERIALS AND METHODS
Study design
The purpose of this study was to generate primate binding TfR bispecific antibodies and determine if they can cross the BBB in nonhuman primates as a means to deliver antibody therapeutics to the central nervous system. Human/monkey cross-reactive antiTfR bispecific antibodies were also assessed in human TfR knock-in mice. For in vivo studies, sample sizes of six C57Bl/6 mice or five cynomolgus monkeys per experimental group were used to account for biological variability among animals and for reliable statistical analysis (detailed methods provided below). For in vitro studies using HEK293 and CHO (Chinese hamster ovary) cell lines, three independent experiments were performed, with technical triplicates per condition. In vivo data collection occurred for a predetermined period of time based on previous TfR antibody PK studies. Data were col lected blindly and/or via assay automation. All data were included, and no animals were excluded from the study.
Human/monkey TfR antibody generation and characterization
Antibody generation. BALB/c mice were coimmunized with human and cyno TfR ECD. Mice demonstrating high serum titers by TfR ELISA and binding to HEK293 cells transiently expressing human or monkey TfR by FACS were fused using X63.Ag8.653 mouse myeloma cells. After fusion, hybridoma supernatants were again screened by ELISA and FACS. Clones that bound both human and cyno TfR in the presence of 1 μM human holo-Tf (R&D, 2914-HT) were selected for further characterization by surface plasmon resonance (SPR) analysis. A clone that had similar affinity to both human and cyno TfR was humanized to generate anti-TfR 1 . AntiTfR C12 was derived from a synthetic antibody phage library that was panned against human TfR ECD. Binding of anti-TfR C12 to TfR was blocked by human holo-Tf. Human isotype control IgG was anti-human glycoprotein D antibody.
Affinity measurements. SPR analysis was performed using a Biacore T100 in HBS-P buffer. Biotinylated human or cyno TfR ECD was captured on a CM5 chip randomly coupled with streptavidin. Affinities of serially diluted TfR1/BACE1 or TfR2/BACE1 were determined using single-cycle kinetics.
Tf competition. MaxiSorp plates were coated with human TfR ECD (2 μg/ml) in phosphate-buffered saline (PBS). Human holo-Tf (1 mg/ml) or PBS was added to the plate for 40 min. Antibody was then added to the wells containing holo-Tf or PBS. Bound antibody was detected with HRP-Goat antiHuman Fcg antibody (Jackson ImmunoResearch, 109-036-098).
HFE competition. A mixture of biotinylated human TfR ECD (2 μg/ml) and serially diluted antibody was added to MaxiSorp plates coated with HFE protein (1 μg/ml) (Novus Biologicals, H00003077-Q01) in PBS for 1 hour. Bound biotinylated human TfR ECD was detected with HRP-streptavidin (GE Healthcare, RPN 4401V).
TfR epitope evaluation. Immobilized anti-TfR 1 and anti-TfR C12 were evaluated for binding to biotinylated human TfR ECD or monovalent M13 phage displaying the human TfR apical domain. Antibodies were coated at 1 μg/ml in PBS on MaxiSorp
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Bispecific antibody generation. AntiTfR 1 , anti-TfR 2 , and anti-BACE1 were used to generate bispecific antibodies using the knob-in-hole bispecific antibody construction technology (6, 9) . In addition to the knob and hole mutations in the Fc for anti-TfR (hole) and anti-BACE1 (knob), both half-antibodies contain mutations in the Fc region that abrogated effector function (N297G). The knob and hole half-antibodies were expressed and purified separately from CHO, and the bispecific antibody was assembled by reductive annealing. After assembly, bispecific antibodies were purified by hydrophobic interaction chromatography. Homogeneity and purity of the final antibodies were confirmed by liquid chromatographymass spectroscopy.
Cellular Aβ x-40 assays
Aβ x-40 production was measured in dissociated cortical neuronal cultures prepared from E16.5 C57BL/6J mice. Neurons were plated at 2.4 × 10 4 cells per well in a 96-well plate and grown for 5 days in vitro. Fresh medium containing anti-BACE1 or anti-TfR/ BACE1 was incubated with the neurons for 24 hours. Medium was harvested and assayed for Aβ x-40 using a sensitive mouse Aβ x-40 ELISA (see below for details). Aβ x-40 values were normalized for cell viability, as determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Experiments were performed at least three times, and each point in each experiment was repeated in duplicate. Data were plotted using a four-parameter nonlinear regression curve using GraphPad Prism.
Generation of human TfR knock-in mouse
The construct for targeting human TFRC cDNA into the C57BL/6 Tfrc locus in embryonic stem (ES) cells was made using a combination of recombineering (15, 16) and standard molecular cloning techniques. Briefly, a cassette (human TFRC cDNA, SV40 pA, and frt-PGK-em7-Neo-BGHpA-frt) flanked by short homologies to the mouse Tfrc gene was used to modify a Tfrc C57BL/6J bacterial artificial chromosome (BAC) (RP23 BAC library) by recombineering. The human TFRC cDNA cassette was inserted at the endogenous ATG, and the remainder of Tfrc exon 2 plus the beginning of intron 2 were deleted. The targeted region in the BAC was then retrieved into pBlight-TK (15) along with flanking genomic Tfrc sequences as homology arms for ES cell targeting. Specifically, the 2950-base pair (bp) 5′ homology arm corresponds to (assembly NCBI37/mm9) chr.16:32,610,333-32,613,282, and the 2599-bp 3′ homology arm corresponds to chr.16:32,613,320-32,615,918. The final vector was confirmed by DNA sequencing. The Tfrc/TFRC KI vector was linearized with Not I, and C57BL/6N C2 ES cells were targeted using standard methods (G418-positive and gancyclovir-negative selection). Positive clones were identified using polymerase chain reaction (PCR) and TaqMan analysis and confirmed by sequencing of the modified locus. Correctly targeted ES cells were transfected with an Flpe plasmid to remove Neo, and ES cells were then injected into blastocysts using standard techniques. Germline transmission was obtained after crossing resulting chimeras with C57BL/6N females.
Measuring antibody concentrations and mouse Aβ x-40 in brain and plasma
The animals' care was in accordance with Genentech Institutional Animal Care and Use Committee (IACUC) guidelines. For wild-type mice, female C57BL/6 mice ages 6 to 8 weeks were used. For huTfR KI/WT and KI/KI mice, about 8-week-old males and females were used. Mice were intravenously injected with antibody and taken down at the indicated time after injection. Before perfusion with PBS, whole blood was collected in plasma Microtainer tubes (BD Diagnostics) and spun down at 14,000 rpm for 2 min. Plasma supernatant was isolated for antibody and mouse Aβ x-40 measurements. Brains were extracted, and one hemi-brain was homogenized in 1% NP-40 (Calbiochem) in PBS containing cOmplete Mini, EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics). Homogenized brain samples were rotated at 4°C for 1 hour before spinning at 14,000 rpm for 20 min. Supernatant was isolated for brain antibody measurement. For brain Aβ x-40 measurements, the other hemi-brain was homogenized in 5 M guanidine hydrochloride buffer, and samples were rotated for 3 hours at room temperature before diluting (1:10) in 0.25% casein and 5 mM EDTA (pH 8.0) in PBS containing freshly added aprotinin (20 mg/ml) and leupeptin (10 mg/ml). Diluted homogenates were spun at 14,000 rpm for 20 min, and supernatants were isolated for mouse Aβ x-40 measurements.
PK assays. Antibody concentrations in mouse serum and brain samples were measured using an ELISA. Nunc 384-well MaxiSorp immunoplates were coated with F(ab')2 fragment of donkey anti-human IgG, Fc fragment-specific polyclonal antibody (Jackson ImmunoResearch). After blocking the plates, each antibody was used as a standard to quantify the respective antibody concentrations. Standards and samples were incubated on plates for 2 hours at room temperature with mild agitation. Bound antibody was detected with HRP-conjugated F(ab')2 goat antihuman IgG, Fc-specific polyclonal antibody (Jackson ImmunoResearch). Concentrations were determined from the standard curve using a four-parameter nonlinear regression program. The assay had lower limit of quantitation (LLOQ) values of 3.12 ng/ml in serum and 1.56 ng/ml in brain.
PD assays. Aβ x-40 concentrations in mouse neuronal culture supernatants, plasma, and brain samples were measured using an ELI-SA similar to methods for PK analysis above. Briefly, rabbit polyclonal antibody specific for the C terminus of Aβ 40 (Millipore) was coated onto plates, and biotinylated anti-mouse Aβ monoclonal antibody M3.2 (Covance) was used for detection. The assay had LLOQ values of 1.96 pg/ml in plasma and 39.1 pg/g in brain.
Western blot analysis
Mouse and monkey brain tissue was isolated and homogenized in 1% NP-40 with protease inhibitors as described above. About 20 μg was loaded onto 4 to 12% Bis-Tris Novex gels (Life Technologies). Gels were transferred onto nitrocellulose membranes using the iBlot system (Life Technologies), and Western blotting was performed using Odyssey blocking buffer reagents and secondary antibodies (LI-COR). Human and mouse cross-reactive mouse antiTfR (Life Technologies, clone H68.4; 1:1000) was used to detect total TfR, whereas human TfR was detected by goat anti-human TfR (R&D, AF2474; 1:2000). Rabbit anti-β-actin (Abcam, 8227; 1:2000) served as a loading control. Western membranes were imaged and quantified using manufacturer-supplied software and system (Odyssey/LI-COR).
Immunohistochemistry
Wild-type and human TfR knock-in mice were intravenously injected with control IgG, antiTfR A , or anti-TfR 1 (5 mg/kg), followed by PBS perfusion 1 hour after dosing. Brains were drop-fixed in 4% paraformaldehyde overnight at 4°C, followed by 30% sucrose overnight at 4°C. Brain tissue were sectioned at 35-μm thickness on a sliding microtome, blocked for 1 to 3 hours in 5% bovine serum albumin (BSA) 0.3% Triton, and incubated with 1:200 Alexa Fluor 488 anti-human secondary antibody (Life Technologies) in 1% BSA 0.3% Triton for 2 hours at room temperature. Mounted slides were subsequently analyzed by Leica fluorescence microscopy.
Cynomolgus monkey PK/PD studies
Animals (male cynomolgus macaque aged 3 to 5 years; five animals per group) were surgically prepared with indwelling cannulae inserted into the cisterna magna and connected to a subcutaneous access port to permit CSF sampling. Control IgG (anti-gD, targeting glycoprotein D of herpes simplex virus), anti-TfR 1 /BACE1, or antiTfR 2 /BACE1 was delivered at 30 mg/kg via an intravenous bolus injection into the SCIENCE sciencemag.org saphenous vein. CSF and blood samples were collected at various time points from 11 days before dosing up to 60 days post-dose. Samples were collected at the same time of the day.
A follow-up study to measure brain antibody uptake and Aβ levels was performed using surgically cannulated animals. This study included both naïve animals and animals dosed in the above PK/ PD (after minimum 100-day drug washout). Animals were not re-administered the same treatment they received in the PK/PD study. Control IgG, anti-TfR 1 /BACE1, anti-TfR 2 / BACE1, or anti-BACE1 was delivered at 30 mg/kg via an intravenous bolus injection into the saphenous vein. Twenty-four hours post-dose, brains were perfused and harvested. Brain regions were subdissected and immediately frozen. Brain samples were prepared for PK and Aβ x-40 PD ELISAs using protocols identical to those for mouse tissue described above.
All animal protocols were approved by the IACUC of Genentech and were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.
PK assays. Total antibody concentrations in monkey serum, CSF, and brain samples were measured using monkey-adsorbed sheep anti-human IgG polyclonal antibody (Binding Site) as coat and a monkey-adsorbed goat anti-human IgG antibody conjugated to HRP (Bethyl) as detection. The assay had an LLOQ value of 39.1 ng/ml in serum or CSF and 3.1 ng/ml in brain.
PD assays. The concentrations of total cyno Aβ x-40 in plasma were determined using an Aβ electroluminescence (ECL) assay, and the concentrations of total cyno Aβ x-40 in CSF and brain were determined using a sandwich ELISA. In both cases, the capture antibody, specific for the C terminus of Aβ x-40 (Millipore), was precoated on the plates, and the anti-Aβ monoclonal antibody 6E10 (Covance) was used for detection. The assays had LLOQ values of 60 pg/ml in plasma, 100 pg/ml in CSF, and 50 pg/ml in brain. CSF concentrations of sAPPα and sAPPβ were determined with a sAPPα/sAPPβ multiplex ECL assay. The anti-Aβ monoclonal antibody 6E10 was used to capture sAPPα, whereas an antibody directed against amino acids 591 to 596 of APP was used to capture sAPPβ. Both analytes were detected with an antibody directed against the N terminus of APP. CSF was thawed on ice and then diluted 1:10 into 1% BSA in tris-buffered saline-Tween 20. The assay had LLOQ values of 0.05 and 0.03 ng/ml for sAPPα and sAPPβ, respectively.
Hematology and blood chemistry assays in cynomolgus monkeys and human TfR knock-in mice
For evaluation of red-cell indices in cynomolgus monkeys, about 0.5 ml of blood was collected into K2 EDTA-containing tubes from all animals at 11 and 7 days before dosing and at 1 hour and 1, 7, 14, and 30 days post-dose. The collected blood was assayed for standard hematological parameters within 2 hours after collection using the Siemens ADVIA 120. For evaluation of clinical chemistry parameters including Fe 2+ and TIBC, about 2 ml of blood was collected after an overnight fast from all animals at 11 and 7 days before dosing and at 7, 14, and 30 days post-dose. The collected blood was separated into serum by centrifugation at 4000 rpm for 10 min at 4°C within 1 hour after collection. The serum samples were then assayed for standard clinical chemistry parameters using the Roche COBAS INTEGRA 400 plus.
For evaluation of red-cell indices in huTfR KI mice, about 0.1 ml of blood was collected into K2 EDTA-containing tubes from all animals and assayed for standard hematological parameters within 2 hours of collection using the Sysmex XT-2000iV (Sysmex).
Statistical analysis
All values are expressed as means ± SEM, unless otherwise indicated, and P values were assessed by ordinary one-way ANOVA, with Dunnett's multiple comparisons test. Correlation analysis between brain TfR and antibody concentrations was performed using Graphpad Prism version 6.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/ content/full/6/261/261ra154/DC1 Materials and Methods Fig. S1 . Generation and characterization of a human TfR knock-in mouse model. Fig. S2 . In vitro and in vivo characterization of TfR degradation related to species and affinity. Fig. S3 . PD analysis in monkey after anti-TfR/ BACE1 antibody dosing.
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INTRODUCTION
R
eceptor tyrosine kinases (RTKs) and their respective ligands play important regulatory roles throughout development and stimulate many critical cellular processes. Aberrant signaling by these molecules is implicated in various diseases, especially cancer. Very few RTKs in mammals have no known ligand and are considered "orphan" RTKs. One such receptor is anaplastic lymphoma kinase (ALK), which is present almost exclusively in the nervous system, primarily during embryonic development. Moreover, the gene encoding ALK is mutated or overexpressed in several cancers (1) (2) (3) . Genetic fusions that result in the joining the kinase domain of ALK with various other proteins (for example, EML4-ALK and NMP-ALK) are the main drivers of a subset of non-small cell lung carcinoma and anaplastic large cell lymphoma cases (2), whereas acquired somatic or inherited germline mutations in ALK, or ALK overexpression, are implicated in neuroblastoma and anaplastic thyroid cancer (1, 3) .
Pleiotrophin (PTN) and Midkine (MK), which are two related heparin-binding extracellular molecules, were reported to be physiological ligands for ALK (4, 5) . However, subsequent studies were unable to confirm these results (6) (7) (8) (9) (10) . Ligand interactions with RTKs induce autophosphorylation, receptor endocytosis, and activation of downstream signaling such as signaling pathways involving the kinases AKT and extracellular signalregulated kinase 1/2 (ERK 1/2) (11). To date, no ligand has been identified for ALK that meets these criteria (6) (7) (8) (9) (10) . The extracellular domain (ECD) of mammalian ALK consists of two MAM (meprin/ A5/protein tyrosine phosphatase Mu) domains, which flank an LDL-A (low-density lipoprotein class A) domain and are N-terminal to a glycine-rich region and a putative epidermal growth factor (EGF)-like domain (11, 12) . The ECD is unique among RTKs, sharing high sequence similarity only with leukocyte tyrosine kinase (LTK) in the glycine-rich region and EGF domain. Like ALK, LTK is an orphan RTK (2, 11) . There is a conserved, highly basic 249-amino acid N-terminal region (NTR) in mature vertebrate ALKs. The NTR of ALK has no reported function and is not conserved among invertebrate ALKs or any other protein. Moreover, ligands that bind invertebrate ALKs (Jeb in Drosophila melanogaster and HEN1 in Caenorhabditis elegans) are not conserved in mammals (2) .
Here, we found that heparin is a specific, high-affinity ligand that directly binds the NTR of ALK. Short heparin chains bound monovalently to ALK ECD and antagonized ALK activation; longer heparin chains induced ALK dimerization, activation, and downstream signaling in cultured neuroblastoma cells. We developed monoclonal antibodies (mAbs) that bound to the NTR of ALK, inhibited heparin binding, and prevented heparin-induced ALK activation. Thus, heparin and perhaps other sulfated proteoglycans can function as ALK ligands or co-ligands, suggesting a mechanism similar to binding and activation of fibroblast growth factor receptors (FGFRs) by heparin and FGF (11) .
RESULTS
Heparin activates ALK
The heparin-binding molecules PTN and MK are putative ligands for ALK. However, there are discrepancies among various reports regarding this role for PTN and MK (4) (5) (6) (7) (8) (9) (10) . To investigate the ability of PTN and MK to activate ALK, we tested whether PTN or MK could activate endogenous ALK in cultured neuroblastoma cells (NB1) in the presence or absence of heparin. Similar to other RTKs, ALK autophosphorylation at several tyrosine residues can be used to monitor activation using antibodies against phosphorylated tyrosine or phosphorylation-specific antibodies targeting ALK (11) . Exposing cells to mixtures of heparin and PTN or heparin and MK stimulated robust autophosphorylation of ALK (Fig.  1A) . However, heparin alone was sufficient to induce ALK autophosphorylation to a similar degree as heparin mixed with PTN or heparin mixed with MK (Fig. 1A) , indicating that PTN and MK were entirely dispensable for ALK activation. Moreover, heparin-induced ALK autophosphorylation and phosphorylation of downstream signaling proteins AKT and ERK 1/2 were concentration-dependent (Fig. 1B  and fig. S1 ). Similar to ligand-mediated stimulation of other RTKs (11), heparin stimulation of NB1 cells induced ALK internalization (Fig.  1C and fig. S1 ).
We developed mAbs directed against the ECD of ALK and tested their ability to activate or inhibit ALK. The mAb αALK1 stimulated phosphorylation of ALK and ERK 1/2 (Fig. 1A) and internalization of ALK (Fig. 1C  and fig. S1 ) in NB1 cells. In contrast, a different mAb, αALK2, inhibited the ability of heparin to induce phosphorylation of ALK and ERK 1/2 (Fig. 1A) .
Heparin is a specific, high-affinity ligand for ALK
The above results suggested that heparin is a ligand or co-ligand for ALK, similar to the role of heparin as a co-ligand for all four members of the FGFR family of RTKs (11, 13, 14) . Moreover, RPTPσ (receptor protein tyrosine phosphatase σ), which also T he discovery of streptomycin, a natural antibiotic produced by Streptomyces griseus, marked the beginning of two formative disciplines within the field of infectious diseases-namely, the study of bacterialderived (rather than fungal-or plant-derived) medicinal compounds and the drug treatment of tuberculosis (TB) (1) . This achievement initiated decades of research in the discovery and use of anti-TB drugs, ultimately leading to the development of the 6-month, multidrug regimen currently used for the cure of drug-susceptible TB (2). Unfortunately, failures in the implementation of this curative regimen, which are partly due to the challenges of its complex and lengthy nature, have led to the development and transmission of drugresistant strains of Mycobacterium tuberculosis. Today, TB remains an enormous global health burden, causing an estimated 1.3 million deaths and 8.7 million new cases in 2012, and a growing percentage of TB (more than 30% of new cases in some countries) is multidrug-resistant (3). Thus, new drugs addressing novel M. tuberculosis targets are needed to provide different therapy options for patients with drug-resistant TB and also to both shorten and simplify treatment of drugsensitive TB. Ideally, these new drugs should be combined in regimens tackling both drugsensitive and drug-resistant TB, representing a paradigm shift toward more universally useful TB treatment regimens.
Development of GM analogs
Our primary optimization goals for GM were to increase its potency, metabolic stability, and exposure. Metabolic stability profiling of natural, less abundant analogs of GM identified Pro 8 as a main site of metabolic degradation, supported by the finding that the methyl derivative [methylgriselimycin (MGM)] (Fig. 1) was markedly more stable than GM itself after incubation with human liver microsomes (Table 1) . Because only very small amounts of MGM are produced naturally, a total synthesis route was elaborated to provide access to MGM and related analogs (see supplementary text). Structure-activity relationships of new synthetic GM analogs resulting from this approach confirmed that incorporation of substituents at Pro 8 led to metabolically highly stable compounds and also indicated that increasing lipophilicity considerably increased in vivo exposure in plasma and lungs of mice, as well as in vitro activity against M. tuberculosis (see supplementary text). From these efforts, cyclohexylgriselimycin (CGM) (Fig. 1) was identified. The minimum inhibitory concentration (MIC) values of CGM were 0.06 and 0.2 mg/ml for the drugsusceptible M. tuberculosis strain H37Rv in broth culture and within macrophage-like (RAW264.7) cells, respectively (Table 1) . CGM exhibited timedependent bactericidal activity in vitro (Fig. 2A) . Although the unbound fraction of CGM in plasma was low (0.3 and 0.4% in human and mouse plasma, respectively), the MIC shift of CGM in the presence of human or mouse sera was only SCIENCE sciencemag.org plays a role in the development of the nervous system, binds directly to glycosaminoglycans (15) . Therefore, we investigated the ability of heparin to bind directly and specifically to the ALK ECD.
Analysis of the NTR of ALK revealed a putative heparin-binding motif ( Fig. 2A) , similar to the motif found in FGFRs that is critical for the ability of heparin to act as a co-ligand for FGFR activation (13, 14) . Deletion of the NTR eliminated the ability of heparin to promote autophosphorylation of ALK in transiently transfected human embryonic kidney (HEK) 293 cells ( fig. S2) , indicating that the NTR is required for ALK activation by heparin.
We characterized the biophysical properties of heparin binding to mammalian ALK in vitro. We used the ECD from Canis familiaris (dog ALK), which shares 91.2% identity to the human ECD (16) . Notably, full-length ALK ECD (FL-ECD), but not a truncation mutant of the ALK ECD lacking the NTR (ΔN-ECD), could be purified using heparin-Sepharose chromatography (Fig. 2B) .
Mutating the basic residues in the putative heparin-binding motif of FL-ECD to acidic residues also inhibited binding to the heparin-Sepharose beads (Fig. 2B) . Thus, these data suggest that heparin directly binds to the NTR domain of ALK.
To measure the affinity and specificity of binding between heparin and ALK, we used surface plasmon resonance (SPR). We immobilized biotinylated heparin to a NeutrAvidin surface and tested binding with various concentrations of FL-ECD and ΔN-ECD. The FL-ECD bound with high affinity (K D = 151 nM) (Fig. 3A) , similar to the range of K D s of heparin binding to FGFs and FGFRs (14) . In contrast, ΔN-ECD bound too weakly for a K D to be estimated (Fig. 3B) . Moreover, the disaccharide heparin mimetic sucrose octasulfate (SOS) inhibited binding of FL-ECD to immobilized heparin at a median inhibitory concentration (IC 50 ) of 6.5 μM and an inhibition constant (K i ) of 2.25 μM (Fig. 3, C and D) , indicating a high degree of specificity for the interaction between heparin and ALK.
Heparin chain length correlates with affinity for ALK and ALK oligomerization
We hypothesized that the stoichiometry of the heparin-ALK interaction would depend on heparin chain length, with increasing chain length resulting in greater degrees of ALK oligomerization. The experiments used to determine binding affinity by SPR used heparin with heterogenous chain lengths. To test if there was a correlation between heparin chain length and ALK-binding affinity and oligomerization state, we used purified heparins with various degrees of polymerization (dp), where 1 dp is equal to 1 heparin disaccharide unit. However, it is important to note that these purified heparins were pools of different lengths defined by an average chain length. We used isothermal titration calorimetry (ITC) to quantify the interaction between FL-ECD and heparins with various average chain lengths. For heparin with an average chain length of dp8-9, dp15, or dp25, the molar ratio and affinity of FL-ECD for heparin indicated approximately monovalent (K D = 505 nM), bivalent (K D = 200 nM), and tetravalent or pentavalent (K D = 80 nM) binding, respectively (Fig. 4 , A to C), suggesting that the enhanced affinity of ALK oligomerized on heparin of longer chain lengths is likely due to avidity associated with this interaction.
We used the molecular weight of the ALKheparin complexes in solution to relate the molar ratio of heparin-ALK binding to ALK stoichiometry by subjecting FL-ECD and FL-ECD-heparin complexes to size exclusion chromatography coupled to a multiangle laser light scattering (SEC-MALLS) detector. In the absence of heparin or in the presence of heparins with an average chain length ≤dp10, FL-ECD eluted from the column with an apparent molecular weight equivalent to monomers (Fig. 4D and fig. S3 ). In contrast, in the presence of heparin dp15, a large proportion of FL-ECD eluted as an apparent dimer (Fig. 4D) . In the presence of heparin dp25, FL-ECD eluted across a broad range of apparent molecular weights greater than that of monomeric or dimeric FL-ECD (Fig.  4D) , suggesting a broad range of higher-order ALK oligomerization likely due, at least in part, to the heterogeneity of chain lengths in the average dp25 heparin pool. Unlike FL-ECD, ΔN-ECD did not elute at a different apparent molecular weight in the presence of heparin dp25 (Fig. 4E) , consistent with the observations that ΔN-ECD did not bind to heparin-Sepharose or to the heparin-coated SPR surface (Fig. 2B) .
Heparins of specific chain length and sulfation patterns activate ALK
To relate the stoichiometry of ALK-heparin binding to physiological activation of the receptor, we stimulated NB1 cells with different concentrations of heparin with different similar to the role of heparin as a co-ligand for all four members of the FGFR family of RTKs (11, 13, 14) . (Fig. 3A) , similar to the range K D s of heparin binding to FGFs and FGFRs (14) . In contrast, DN ECD bound too weakly for a K D to be estimated (Fig. 3B) . Moreove the disaccharide heparin mimetic sucrose octasulfate (SOS) inhibite binding of FL-ECD to immobilized heparin at a median inhibitory co centration (IC 50 ) of 6.5 mM and an inhibition constant (K i ) of 2.25 mM (Fig. 3, C and D) , indicating a high degree of specificity for the interactio between heparin and ALK.
Heparin chain length correlates with affinity for ALK and ALK oligomerization
We hypothesized that the stoichiometry of the heparin-ALK interactio would depend on heparin chain length, with increasing chain leng resulting in greater degrees of ALK oligomerization. The experimen used to determine binding affinity by SPR used heparin with hetero enous chain lengths. To test if there was a correlation between hepar chain length and ALK-binding affinity and oligomerization state, w used purified heparins with various degrees of polymerization (dp where 1 dp is equal to 1 heparin disaccharide unit. However, it is im portant to note that these purified heparins were pools of differe lengths defined by an average chain length. We used isothermal titr tion calorimetry (ITC) to quantify the interaction between FL-ECD an heparins with various average chain lengths. For heparin with an averag chain length of dp8-9, dp15, or dp25, the molar ratio and affinity FL-ECD for heparin indicated approximately monovalent (K D = 505 nM bivalent (K D = 200 nM), and tetravalent or pentavalent (K D = 80 nM binding, respectively (Fig. 4, A to C) , suggesting that the enhanced affini of ALK oligomerized on heparin of longer chain lengths is likely due avidity associated with this interaction.
We used the molecular weight of the ALK-heparin complexes in sol tion to relate the molar ratio of heparin-ALK binding to ALK stoichiomet by subjecting FL-ECD and FL-ECD-heparin complexes to size exclusio chromatography coupled to a multiangle laser light scattering (SEC-MALL detector. In the absence of heparin or in the presence of heparins with a average chain length ≤dp10, FL-ECD eluted from the column with an a parent molecular weight equivalent to monomers (Fig. 4D and fig. S3 ). contrast, in the presence of heparin dp15, a large proportion of FL-EC eluted as an apparent dimer (Fig. 4D) . In the presence of heparin dp25, FL ECD eluted across a broad range of apparent molecular weights greater tha phorylated ERK1 and ERK2 (pERK 1/2) using lysates from NB1 cells. In (A), cells were exposed to PTN (100 nM), MK (100 nM), heparin (HEP, 10 mg/ml), aALK2 (10 nM), or aALK1 (10 nM) alone or in the indicated combinations for 10 min. In (B), cells were exposed to heparin at different concentrations (100 to 0.01 mg/ml) for 10 min. MW, molecular weight. (C) Western blot for endogenous ALK using isolated cell surfacebiotinylated proteins or lysates of NB1 cells exposed to heparin (10 mg/ml) or aALK1 (10 nM) for 6 hours. For (A) to (C), "-" indicates unstimulated negative control cells, and the blots are representative of at least two independent experiments.
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Heparins of specific chain length and sulfation patterns activate ALK
To relate the stoichiometry of ALK-heparin binding to physiological activation of the receptor, we stimulated NB1 cells with different concentrations of heparin with different chain lengths and measured ALK autophosphorylation by enzyme-linked immunosorbent assay (ELISA). Heparin with average chain lengths greater than dp15, but not less than dp15, induced autophosphorylation of ALK (Fig. 5A) , suggesting that ALK dimerization and higher-order oligomerization promote receptor activation. We tested whether SOS, which is equivalent to heparin with a chain length of dp1 and thus should not induce dimerization, inhibited heparin-induced activation of ALK in NB1 cells. We found that SOS reduced the ability of mixed chain length heparin to promote autophosphorylation of ALK and phosphorylation of AKT and ERK 1/2 in a concentrationdependent manner (Fig. 5B) .
Heparin is an experimental proxy for physiological ligands used to study the effects of glycosaminoglycans on signaling by RTKs (2, 13, 14, 17) . Glycosaminoglycans other than heparin are likely to be the physiologically relevant ALK ligand or co-ligand in vivo. Moreover, the sulfation pattern of glycosaminoglycans can influence binding and activation state of receptors, as observed with RPTPs (14) . Therefore, we tested whether exposing NB1 cells to differentially sulfated heparin or other glycosaminoglycans with different sulfation patterns activated ALK. We found that heparin, oversulfated heparin, and dextran sulfate induced autophosphorylation of ALK, whereas chondroitin sulfate, heparan sulfate, and various other specifically desulfated heparins did not (Fig. 5, C and D) . broad range of highererization likely due, at heterogeneity of chain age dp25 heparin pool. N-ECD did not elute at molecular weight in the arin dp25 (Fig. 4E) , observations that DNto heparin-Sepharose or d SPR surface (Fig. 2B) .
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suggesting that ALK dimerization and higher-order oligomerization promote receptor activation. We tested whether SOS, which is equivalent to heparin with a chain length of dp1 and thus should not induce dimerization, inhibited heparin-induced activation of ALK in NB1 cells. We found that SOS reduced the ability of mixed chain length heparin to promote autophosphorylation of ALK and phosphorylation of AKT and ERK 1/2 in a concentration-dependent manner (Fig. 5B) .
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An antibody targeting the ECD of ALK inhibits heparin binding and heparin-induced activation of ALK mAbs that directly inhibit ligand binding or receptor dimerization are useful for treatments of various clinical indications. ALK plays a role in neuroblastoma pathogenesis (1, 2) . Therefore, we tested several mAbs targeting either the N-terminal or C-terminal half of the human ALK ECD for the ability to inhibit heparin binding using an SPR competition assay. The mAb aALK3 decreased the SPR refractive index (Fig. 6A) , indicating that aALK3 disrupted the interaction of FL-ECD with the heparin-coated surface (increased K off for FL-ECD). In contrast, seven other mAbs increased the SPR refractive index (Fig. 6A) , indicating that these mAbs did not compete with FL-ECD for heparin binding and presumably bound at an independent site on FL-ECD, increasing the total mass on the heparincoated surface. In the absence of FL-ECD, aALK3 and six of the other seven mAbs did not bind to the heparin-coated surface ( fig. S4 ), indicating very little nonspecific direct binding to the surface.
Immunoblot analysis indicated that aALK3 bound to the NTR of ALK ( fig. S5 ), suggesting that aALK3 directly competes with heparin at the heparin-binding site and should prevent activation of ALK by heparin. Thus, we tested whether aALK3 inhibited the ability of heparin to induce autophosphorylation of ALK. The whole immunoglobulin G (IgG) aALK3 mAb stimulated ALK autophosphorylation in NB1 cells ( fig. S6 ), suggesting that the antibody caused receptor dimerization, which is an established mechanism for antibodies that bind RTKs and act as agonists (11) . Thus, we generated a monovalent Fab fragment derived from aALK3 (aALK3-Fab). aALK3-Fab inhibited heparin-induced autophosphorylation of ALK with an estimated IC 50 <100 nM (Fig. 6B) . Likewise, aALK3-Fab inhibited heparin-induced phosphorylation of AKT and ERK 1/2 (Fig. 6B ).
DISCUSSION
We found that heparin bound to ALK and induced ALK tyrosine autophosphorylation, suggesting a role for sulfated glycosaminoglycans and associated proteoglycans as physiological ligands for ALK. One possible mechanism of ALK activation is that sulfated carbohydrate moieties of a proteoglycan bind to the positively charged region in the NTR of ALK and the protein core of the same proteoglycan binds to another region in ALK. Another potential mechanism is that the sulfated carbohydrate moieties of the proteoglycan could act together with a second, yet to be identified, protein ligand to stimulate ALK dimerization and activation similar 
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Heparin is an experimental proxy for physiological ligands used to study the effects of glycosaminoglycans on signaling by RTKs (2, 13, 14, 17) . Glycosaminoglycans other than heparin are likely to be the physiologically relevant ALK ligand or co-ligand in vivo. Moreover, the sulfation pattern of glycosaminoglycans can influence binding and activation state of receptors, as observed with RPTPσ (14) . Therefore, we tested whether exposing NB1 cells to differentially sulfated heparin or other glycosaminoglycans with different sulfation patterns activated ALK. We found that heparin, oversulfated heparin, and dextran sulfate induced autophosphorylation of ALK, whereas chondroitin sulfate, heparan sulfate, and various other specifically desulfated heparins did not (Fig. 5, C  and D ).
An antibody targeting the ECD of ALK inhibits heparin binding and heparininduced activation of ALK
mAbs that directly inhibit ligand binding or receptor dimerization are useful for treatments of various clinical indications. ALK plays a role in neuroblastoma pathogenesis (1, 2) . Therefore, we tested several mAbs targeting either the N-terminal or C-terminal half of the human ALK ECD for the ability to inhibit heparin binding using an SPR competition assay. The mAb αALK3 decreased the SPR refractive index (Fig. 6A) , indicating that αALK3 disrupted the interaction of FL-ECD with the heparin-coated surface (increased K off for FL-ECD). In contrast, seven other mAbs increased the SPR refractive index (Fig.  6A) , indicating that these mAbs did not compete with FL-ECD for heparin binding and presumably bound at an independent site on FL-ECD, increasing the total mass on the heparin-coated surface. In the absence of FL-ECD, αALK3 and six of the other seven mAbs did not bind to the heparin-coated surface ( fig. S4 ), indicating very little nonspecific direct binding to the surface.
Immunoblot analysis indicated that αALK3 bound to the NTR of ALK ( fig. S5 ), suggesting that αALK3 directly competes with heparin at the heparin-binding site and should prevent activation of ALK by heparin. Thus, we tested whether αALK3 inhibited the ability of heparin to induce autophosphorylation of ALK. The whole immunoglobulin G (IgG) αALK3 mAb stimulated ALK autophosphorylation in NB1 cells ( fig. S6) , suggesting that the antibody caused receptor dimerization, which is an established mechanism for antibodies that bind RTKs and act as agonists (11) . Thus, we An antibody targeting the ECD of ALK inhibits heparin binding and heparin-induced activation of ALK mAbs that directly inhibit ligand binding or receptor dimerization are useful for treatments of various clinical indications. ALK plays a role in neuroblastoma pathogenesis (1, 2) . Therefore, we tested several mAbs targeting either the N-terminal or C-terminal half of the human ALK ECD for the ability to inhibit heparin binding using an SPR competition assay. The mAb aALK3 decreased the SPR refractive index (Fig. 6A) , indicating that aALK3 disrupted the interaction of FL-ECD with the heparin-coated surface (increased K off for FL-ECD). In contrast, seven other mAbs increased the SPR refractive index (Fig. 6A) , indicating that these mAbs did not compete with FL-ECD for heparin binding and presumably bound at an independent site on FL-ECD, increasing the total mass on the heparincoated surface. In the absence of FL-ECD, aALK3 and six of the other seven mAbs did not bind to the heparin-coated surface ( fig. S4 ), indicating very little nonspecific direct binding to the surface.
DISCUSSION
We found that heparin bound to ALK and induced ALK tyrosine autophosphorylation, suggesting a role for sulfated glycosaminoglycans and associated proteoglycans as physiological ligands for ALK. One possible mechanism of ALK activation is that sulfated carbohydrate moieties of a proteoglycan bind to the positively charged region in the NTR of ALK and the protein core of the same proteoglycan binds to another region in ALK. Another potential mechanism is that the sulfated carbohydrate moieties of the proteoglycan could act together with a second, yet to be identified, protein ligand to stimulate ALK dimerization and activation similar The identification of heparin as a ligand or co-ligand provides insight and tools for investigating ALK biology. Little is known about the function of mammalian ALK. In Drosophila, constitutive activation of ALK by Jeb is essential for maintaining normal brain metabolism during starvation (18) . In addition to its role in neurobiology, ALK signaling has been implicated in driving several types of cancer (1) (2) (3) . Similar to other RTKs, ligand-mediated increases in ALK signaling may contribute to tumorigenesis. Thus, the discovery of heparin as a bona fide ALK ligand provides mechanistic understanding of ALK activation and potential methods to inhibit oncogenic ALK by targeting its ECD.
MATERIALS AND METHODS
Cloning, expression, and purification of FL-ECD, DN-ECD, and heparin-binding motif mutations
The nucleotide sequence coding for amino acids 1 to 1037 of dog ALK (encoding FL-ECD) (16) was synthesized by Blue Heron. An 8X-His tag was added to the 3′ end, followed by a stop codon. An Xho I site was added upstream of the start codon, and an Xba I site was added directly after the stop codon. The construct was subcloned into pcDNA3.3. DN-ECD was produced by polymerase chain reaction-mediated deletion (19) of amino acids 21 to 263 using FL-ECD as the template. The mutations in the heparinbinding motif were produced using site-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis protocol developed by Stratagene (catalog no. 200523). All plasmids were verified by sequencing of the complete open reading frame.
To produce recombinant His-tagged FL-ECD and DN-ECD, plasmids were transiently transfected into HEK293-S cells grown in Dulbecco's modified Eagle's medium-F12 with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin using the Lipofectamine 2000 as per the manufacturer's instructions (Invitrogen). The culture medium was switched www.SCIE to the paradigm established for heparin and FGF stimulation of FGFR (11) . LTK and ALK share homology in the glycine-rich region and EGF-like ECD of LTK, suggesting that these regions likely serve as the bindin for an unidentified ligand. Thus, although ALK and LTK may identical or related ligands, ALK is likely activated by two or more co-lig a sulfated glycosaminoglycan-linked proteoglycan that binds the NTR ligand that binds to the glycine-rich and EGF-like repeat of the ECD The identification of heparin as a ligand or co-ligand provides in and tools for investigating ALK biology. Little is known about the tion of mammalian ALK. In Drosophila, constitutive activation of by Jeb is essential for maintaining normal brain metabolism during vation (18) . In addition to its role in neurobiology, ALK signaling has implicated in driving several types of cancer (1) (2) (3) . Similar to other R ligand-mediated increases in ALK signaling may contribute to tum genesis. Thus, the discovery of heparin as a bona fide ALK ligand pro mechanistic understanding of ALK activation and potential metho inhibit oncogenic ALK by targeting its ECD.
The nucleotide sequence coding for amino acids 1 to 1037 of dog (encoding FL-ECD) (16) was synthesized by Blue Heron. An 8X-H was added to the 3′ end, followed by a stop codon. An Xho I site added upstream of the start codon, and an Xba I site was added dir after the stop codon. The construct was subcloned into pcDNA3.3. DNwas produced by polymerase chain reaction-mediated deletion (19) of a acids 21 to 263 using FL-ECD as the template. The mutations in the hep binding motif were produced using site-directed mutagenesis usin QuikChange II Site-Directed Mutagenesis protocol developed by Strata (catalog no. 200523). All plasmids were verified by sequencing of the plete open reading frame.
To produce recombinant His-tagged FL-ECD and DN-ECD, plas were transiently transfected into HEK293-S cells grown in Dulbe modified Eagle's medium-F12 with 10% fetal bovine serum (FBS 1% penicillin and streptomycin using the Lipofectamine 2000 as pe SCIENCE sciencemag.org generated a monovalent Fab fragment derived from αALK3 (αALK3-Fab). αALK3-Fab inhibited heparin-induced autophosphorylation of ALK with an estimated IC 50 <100 nM (Fig.  6B) . Likewise, αALK3-Fab inhibited heparininduced phosphorylation of AKT and ERK 1/2 (Fig. 6B) .
DISCUSSION
We found that heparin bound to ALK and induced ALK tyrosine autophosphorylation, suggesting a role for sulfated glycosaminoglycans and associated proteoglycans as physiological ligands for ALK. One possible mechanism of ALK activation is that sulfated carbohydrate moieties of a proteoglycan bind to the positively charged region in the NTR of ALK and the protein core of the same proteoglycan binds to another region in ALK. Another potential mechanism is that the sulfated carbohydrate moieties of the proteoglycan could act together with a second, yet to be identified, protein ligand to stimulate ALK dimerization and activation similar to the paradigm established for heparin and FGF stimulation of FGFR (11) . LTK and ALK share homology in the glycine-rich region and EGF-like repeat. The glycine-rich region and EGF-like repeat comprise the entire ECD of LTK, suggesting that these regions likely serve as the binding site for an unidentified ligand. Thus, although ALK and LTK may share identical or related ligands, ALK is likely activated by two or more co-ligands: a sulfated glycosaminoglycanlinked proteoglycan that binds the NTR and a ligand that binds to the glycine-rich and EGFlike repeat of the ECD.
The identification of heparin as a ligand or co-ligand provides insight and tools for investigating ALK biology. Little is known about the function of mammalian ALK. In Drosophila, constitutive activation of ALK by Jeb is essential for maintaining normal brain metabolism during starvation (18) . In addition to its role in neurobiology, ALK signaling has been implicated in driving several types of cancer (1-3). Similar to other RTKs, ligand-mediated increases in ALK signaling may contribute to tumorigenesis. Thus, the discovery of heparin as a bona fide ALK ligand provides mechanistic understanding of ALK activation and potential methods to inhibit oncogenic ALK by targeting its ECD.
MATERIALS AND METHODS
Cloning, expression, and purification of FL-ECD, ΔN-ECD, and heparin-binding motif mutations
The nucleotide sequence coding for amino acids 1 to 1037 of dog ALK (encoding FL-ECD) (16) was synthesized by Blue Heron. An 8X-His tag was added to the 3′ end, followed by a stop codon. An Xho I site was added upstream of the start codon, and an Xba I site was added directly after the stop codon. The construct was subcloned into pcDNA3.3. ΔN-ECD was produced by polymerase chain reaction-mediated deletion (19) of amino acids 21 to 263 using FL-ECD as the template. The mutations in the heparin-binding motif were produced using site-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis protocol developed by Stratagene (catalog no. 200523). All plasmids were verified by sequencing of the complete open reading frame.
To produce recombinant His-tagged FL-ECD and ΔN-ECD, plasmids were transiently transfected into HEK293-S cells grown in Dulbecco's modified Eagle's medium-F12 with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin using the Lipofectamine 2000 as per the manufacturer's instructions (Invitrogen). The culture medium was switched to Opti-MEM just before transfection. Transfected cells were incubated in Opti-MEM for 4 days. The medium was collected and clarified by centrifugation and vacuum filtration (0.45-μm polyvinylidene difluoride filter).
To isolate His-tagged proteins, nickelSepharose excel beads (GE Healthcare) were added to the clarified medium and incubated overnight at 4°C with agitation. Beads were washed with 30 column volumes (CVs) of phosphate-buffered saline (PBS) and 30 CVs of 20 mM imidazole in buffer A [25 mM Hepes, 150 mM NaCl, and 10% glycerol (pH 7.4)]. Elution was performed with 250 mM imidazole in buffer A. Fractions were collected and further purified by SEC on a HiLoad Superdex 200 column preequilibrated with buffer A. Fractions containing His-tagged proteins (estimated to be >97% pure) were collected, combined, and concentrated to 10 mg/ml using a 30,000-MWCO (molecular weight cutoff) concentrator device (Sartorius Stedim). For heparin-Sepharose chromatography experiments, eluted protein from the nickel column was dialyzed against buffer A without imidazole and then incubated with heparin-Sepharose beads (GE Healthcare) overnight. Heparin-Sepharose beads were washed with 50 CVs of buffer A and eluted in 25 mM Hepes, 1 M NaCl, and 10% glycerol at pH 7.4.
Generation of mAbs and αALK3-Fab
mAbs were purified from hybridoma cultures, derived from mice immunized with the ALK ectodomain (either M1-G460 or T637-S1038, which was synthesized, cloned, and expressed with 8X-His tags as described above for the dog FL-ECD and ΔN-ECD). Conditioned hybridoma medium was passed through a protein A column and washed with PBS, and mAbs were eluted with 0.1 M glycine (pH 2.7) and immediately neutralized with 1 M tris (pH 7.5). The buffer containing the purified mAbs was changed to PBS by tangential flow filtration.
αALK3-Fab was generated from the parental αALK3 IgG antibody and purified using the Fab Preparation Kit (Thermo-Pierce, catalog no. 44985). The Fab fragment was further purified by SEC, and the buffer was changed to PBS using a HiLoad Superdex 200 26/600 column.
NTR epitope mapping
The NTR of human ALK used for the experiment shown in fig. S5 was cloned into pET28b (Novagen) and expressed in BL21-(de3) Escherichia coli cells. Inclusion bodies were isolated and solubilized in Laemmli sample buffer for use in SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Solubilized inclusion bodies containing the NTR were used for Western blot.
sciencemag.org SCIENCE ALK internalization assay NB1 cells were exposed to heparin or αALK1 for 6 hours. Cells were washed with PBS three times and incubated with cellimpermeable Sulfo-NHS-LC-Biotin (0.5 mg/ ml) (Thermo-Pierce, catalog no. 21435) in PBS for 1 hour. Then, cells were washed with PBS containing 0.1 M glycine and lysed with 50 mM Hepes, 150 nM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 25 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, and Roche Complete Protease Inhibitor Cocktail. Biotinylated proteins were enriched with 50 μl of NeutrAvidin agarose beads (Thermo-Pierce, catalog no. 29200) in 500 μl of lysate at room temperature for 1 hour, eluted overnight with sample buffer containing β-mercaptoethanol, and resolved by SDS-PAGE. Protein was transferred to nitrocellulose, and membranes were immunoblotted with an antibody for ALK.
Surface plasmon resonance SPR experiments were performed using a Biacore T100 instrument (GE Healthcare) at 25°C. All reagents were dialyzed into a buffer composed of 25 mM Hepes, 150 mM NaCl, and 10% glycerol at pH 7.4. Biotinylated heparin (≥97% pure, Sigma, catalog no. B9806-10MG) was further purified using PD-10 prepacked columns (GE Healthcare, catalog no. 17-0851-01) to remove free biotin. Biotinylated heparin was immobilized on an assembled NeutrAvidin (Thermo-Pierce) surface (amine coupled on a CM4 Series-S Biacore chip). Three surfaces were produced with different concentrations of biotinylated heparin by varying contact time from 48 to 240 s. Threefold dilutions of FL-ECD and ΔN-ECD were injected sequentially and in random order over a reference surface without heparin and three heparin surfaces. The surface was regenerated between cycles with 2.5 M NaCl and 5 mM acetic acid at pH 4.5. For the SOS competition assay, serial dilutions of SOS were preincubated with 0.350 μM FL-ECD and then injected over the surface. IC50 and K i values were derived by plotting the log-transformed concentration of SOS as a function of fractional bound FL-ECD at saturation and applying the ChengPrusoff equation.
Isothermal titration calorimetry
ITC assays were performed using a MicroCal VP-ITC instrument (Malvern) with a 1.3-ml cell volume and 250-μl ligand syringe with 25 mM Hepes, 150 mM NaCl, and 10% glycerol at pH 7.4 at 25°C. Each macromolecule and ligand was extensively dialyzed against this buffer. Heparins of defined average length were purchased from Neoparin. For dp25 heparin binding to ALK, 1.43 ml of 8.3 μM ALK was placed in the cell. Two hundred fifty microliters of 44 μM dp25 heparin was titrated in 8-μl increments. For dp15 heparin binding to ALK, 1.43 ml of 6 μM SUPPLEMENTARY MATERIALS www.sciencesignaling.org/cgi/content/full/8/360/ ra6/DC1 Fig. S1 . Quantification of heparin-induced ERK 1/2 activation and ALK internalization. ALK was placed in the cell. Two hundred fifty microliters of 60 μM dp25 heparin was titrated in 8-μl increments. For dp8-9 heparin binding to ALK, 1.43 ml of 10 μM ALK was placed in the cell. Two hundred fifty microliters of 150 μM dp25 heparin was titrated in 10-μl increments. Data were collected and then processed, corrected for heat of dilution, and analyzed using "Origin 5.0 with MicroCal ITC feature" software. Data were fit to a one-site model by nonlinear least squares regression from which the calculated affinities and stoichiometries were derived.
Size exclusion chromatographymultiangle laser light scattering
The light scattering data were collected using a Superose 6 column in tandem with a Superdex 75, 10/300, HR SEC column (for FL-ECD experiments) or a Superose 6 column in tandem with a second Superose 6 column (for ΔN-ECD experiments) (GE Healthcare), connected to high-performance liquid chromatography (HPLC) System (Agilent 1200, Agilent Technologies) equipped with an autosampler. The elution from SEC was monitored by a photodiode array ultraviolet (UV) and visible light detector (Agilent Technologies), differential refractometer (Optilab rEX, Wyatt Corp.), and a static and dynamic MALLS detector [HELEOS II with QELS (quasielastic light scattering) capability, Wyatt Corp.]. The SEC detection system was equilibrated in 150 mM NaCl, 25 mM Hepes (pH 7.4), and 10% glycerol at a flow rate of 0.4 ml/min. ChemStation software (Agilent Technologies) was used to control the HPLC and data collection from the multiwavelength photodiode array UV and visible light detector. ASTRA software (Wyatt Corp.) was used to collect data from the refractive index detector and the light scattering detectors, and the UV trace at 280 nm, sent from the photodiode array detector, was recorded. Average molecular masses were determined across the entire elution profile in the intervals of 1 s from static light scattering measurement using ASTRA software as previously described (20) . Heparin-ALK complexes were prepared by mixing heparin (purchased from Neoparin) in excess with FL-ECD. 
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Deeper insights into biological realities Detection of interactions
Interactions between biomolecules are the key drivers of biological processes. For example, protein-protein interactions ensure signal transduction across membranes via G protein-coupled receptor (GPCR), maintain the structure of complexes by chaperones, or enable the enzymatic modification of proteins via post-translational phosphorylation. Hundreds of thousands of interactions have been identified and collected in databases, for example IntAct (http://www.ebi.ac.uk/intact/). Such a database allows the interactions to be assembled into pathways and studied further. Yet the majority of protein interactions probably remain undiscovered.
Homing in on the nature of interactions
GPCRs are transmembrane receptors that sense molecules outside the cell and activate signal transduction pathways, leading to cellular responses. The work of Suzuki and coworkers (1), based at Tokyo University, has increased the understanding of the interactions and guanine-nucleotidedependent conformational changes involved in transient GPCR-signaling. Their work represents a typical approach to the study of interactions, in this case between LARG, a guanine nucleotide exchange factor for Rho, and Gα 13 , a GPCR subunit. The study starts with detailed interaction analysis, and concludes by looking at the thermodynamics of conformational changes.
Which domains interact?
The first step for Suzuki and co-workers was to determine if interactions occur, and their dependency on effector molecules. They used a cell-based assay with cells transfected with myc-tagged deletion constructs of LARG with different combinations of domains, and Gα 13 . They showed that Gα 13 interacts directly with LARG through its RH domain, DH/PH domains, and C-terminal region (Fig 1) . The next step was to characterize these interactions with SPR-based assays using Biacore 3000.
SPR-based analysis confirms the interactions and provides more detail
Studies were based on two variants of Gα 13 : Gα i/13 , a chimera of Gα 13 , and Gα i/13 KA, which has a mutation, K204A, in the domain that recognizes the RH domain of LARG. These variants could be activated with AMF (AlCl 3 , MgCl 2 , and NaF).
The variants of Gα 13 were immobilized on the surface of Sensor Chip CM5 using amine coupling chemistry, and activated by including AMF in the running buffer (Fig 2) . Solutions of LARG constructs at different concentrations were flowed over the sensor surface in the presence or absence of AMF, followed by a regeneration buffer.
The results for Gα i/13 clearly showed that AMF activation is necessary for all interactions and that these involve RH, DH, and PH domains of LARG. Comparing LARG construct DPC (DH, PH, and C-terminal) and DH/PH (DH and PH domains, only) indicated that the C-terminal is also involved. Suzuki and co-workers also used Gα i/13 KA to confirm that the mutation at Lys-204 (K204A) significantly reduced the affinity of Gα 13 for the RH domain of LARG, without affecting interactions with the DH and PH domains. The position of the K204A mutation in the RH-binding region of Gα i/13 KA is also shown.
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Determining the extent of the interaction
The raw data represented in these sensorgrams was used to determine kinetic data: association rate constant (k a ), dissociation rate constant (k d ) and equilibrium constant (K D ). The relative affinity (in parentheses) of the LARG constructs for Gα i/13 increased in the order RH (×1) < RH-DH-PH (×2) < RH-DH-PH-C terminal (×20). The interaction involving the C-terminal therefore decreased the dissociation rate of the Gα i/13 -LARG complex considerably. The association of the RH domain with the Gα 13 surface, including Lys-204, probably induces the conformational change of the DH/PH domains of LARG necessary for its biological action.
What are the dynamics?
Suzuki and co-workers decided to investigate the dynamics of the conformational changes induced by Gα 13 -LARG binding (especially the contribution of the RH-domain and the DH/PH domains) by determining the thermodynamics of these interactions. This involved using Biacore T100 to analyze the interactions between LARG and Gα i /13 immobilized on Sensor Chip CM5 (Fig 3) . The interaction between RH-DH-PH and Gα 13 had a higher free energy change than the RH/Gα 13 interaction, which is consistent with the higher affinity of the LARG-RH-DH-PH construct compared with the LARG-RH construct (Fig 3) . Of particular interest was the fact that the Gα 13 -RH interaction is enthalpy-driven and entropically unfavorable. This contrasted with the binding of the RH-DH-PH construct to Gα 13 , which is less favorable than LARG-RH with respect to enthalpy, but is entropy-driven with a positive ΔS 0 . In general, a large negative heat capacity change (ΔC p 0 ) in a protein-protein interaction indicates the removal of water-accessible hydrophobic surface area coupled to conformational changes. Indeed, the researchers were able to conclude that the interaction between Gα13 and the RH domain of LARG triggers conformational changes that bury an exposed hydrophobic surface to create a large complementary surface, thereby promoting complex formation. 
Kinetics
The cell is a dynamic system. So, identifying interactions is just the first step in interaction analysis and most often leads to an investigation of kinetics, to answer the following questions:
• How fast do molecules bind (association)?
• How fast do complexes fall apart (dissociation)?
Kinetics therefore determine whether a complex forms or dissociates within a given time span. Association and dissociation measurements can also be used to determine how much complex is formed at equilibrium (the steady state where association balances dissociation). This is the affinity of the interaction.
A stable basis for kinetics studies
Determining the residence time or half-life of a drug on its target receptor is a critical point in drug discovery. SPRbased assays are routinely used in biophysical screening of soluble drug targets to determine equilibrium binding constants, kinetic rate constants and thermodynamic parameters. It becomes more challenging to analyze membrane protein targets, which can be destabilized by detergent-extraction and lose their native ligand-binding capability. This problem is particularly acute in the study of GPCRs, a very important group of drug targets. One method for engineering stability into receptors, called Stabilized Receptor, or StaR™, has enabled the study of receptors that were previously difficult to analyze, including GPCRs. These receptors can be purified in large quantities, retain correct folding, and are stabilized to such an extent that they can readily be used in binding assays. Robertson and co-workers at Heptares Therapeutics in the UK, have used SPR-based assays to analyze the kinetics of interactions between drug candidates and StaR molecules (2) .
Designing in protein stability
The researchers first determined the success of mutagenesis by determining the thermostability of over three hundred mutations, and combinations of mutations with a method involving stabilization with a radioactive agonist. Stability with respect to detergents was also tested. The most promising candidates were then selected for recombination and kinetic analysis.
Determining kinetics with more accuracy and throughput
The kinetics of interactions involving GPCRs are usually determined by measuring dissociation rates of a radioactive ligand in the presence or absence of the test compound. Having confirmed that radio-ligand binding studies and SPR-based assays gave similar results for affinity, Robertson and co-workers found that SPR-based assays enabled analysis of kinetics on solid-phase and thereby provided a simpler, higher throughput, and more accurate method compared to conventional methods.
The researchers used SPR to examine the kinetics of one stabilized construct, A 2A -Star2, in more detail. The kinetic characterization of five A 2A ligands, with relative molecular masses in the range 285 to 345, using SPR detection assays is shown in Figure 4 . The binding was concentration dependent, and showed high reproducibility between triplicates. Binding parameters could be determined after fitting the sensorgrams to a 1:1 model. The range of association and dissociation rate constants displayed by these antagonists gave a 10 000-fold range in affinities. In addition, the validity of the approach was confirmed by the fact that affinity constants closely correlated with those obtained in equilibrium binding studies on the wild-type receptor in membranes. The ability to stabilize receptors opens up new possibilities for the analysis of relatively unstable GPCRs, using crystallography to probe structure, and SPR to analyze kinetics. This approach should lead to the identification of ligand candidates with the desired interaction properties. 
Structure and function
The structure of a biomolecule is usually critical to its function. The structure may be static, but is more often dynamic and influences, or is influenced by, interactions with other biomolecules. Very often, as in the case of enzymes, changes in structure are instrumental in the function.
Protein structure may be determined by sequencing and then applying biophysical methods such as X-ray crystallography and NMR to determine the three-dimensional, structure in interaction with cofactors where necessary. Understanding the roles played by conformational changes and structure in interactions requires application of other methods, such as biochemical assays and biophysical techniques, such as SPRbased assays.
Find out how proteins work by looking at their domains
The three-dimensional structure of a protein can be determined from its sequence and by applying biophysical techniques, such as X-ray crystallography and NMR spectroscopy. The structural domains within the protein can then be dissected out and isolated, which then makes it possible to apply SPR-based assays to investigate interactions between domains. This deepens the understanding of the dynamics that link structure and function. Luna-Vargas and co-workers, based at The Netherlands Cancer Institute, have applied this approach in the study of an enzyme involved in the processing of ubiquitin (3).
Ubiquitin (Ub) is a small, ubiquitous regulatory protein with a number of functions, including being used by conjugating enzymes to label proteins that are to be processed. This discovery led to the award of the Nobel Prize for chemistry to Aaron Ciechanover, Ayram Hershko, and Irwin Rose in 2004. Deubiquinating enzymes (DUBs), such as USP4, balance this labeling activity by removing Ub from the target molecule. Luna-Vargas and co-workers used SPR detection to investigate the structural elements of ubiquitin-specific protease 4 (USP4) that control its deubiquinating activity.
Determining the structural elements to be isolated
The researchers first determined the structure of the catalytic domain of USP4, which consists of two regions, D1 and D2, using X-ray crystallography. They also prepared a number of constructs comprising various combinations of the protein domains -for example a construct with an insert between D1 and D2 that contained an Ubiquitin-like domain (Ubl), as in the native protein. In vitro de-ubiquitinating assays indicated that including the Ubl-insert in USP4-D1D2 (USP4-D1-Ubl-insert-D2) reduced catalytic activity, which suggested that the Ubl-insert inhibits the DUB activity of USP4 through an autoregulatory mechanism.
Exploring the interactions
The researchers then used SPR-based assays to determine if the Ubl-insert interacts directly with the catalytic domain, USP4-D1D2. GST (glutathione S-transferase)-fused fragments were immobilized on α-GST antibodies that had been lysine-coupled to Sensor Chip CM5 (Fig 5A) . USP4D1-D2 was flowed over the surface and interactions were detected using Biacore T100. Luna-Vargas and co-workers showed that the affinities of the Ubl-insert, and Ubl alone, for USP4-D1D2 are indeed similar to that of Ub itself (Fig 5B-D) . 
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Ubl T a r g e t Ubl competes with Ub SPR-based detection was used in a competition assay, involving flowing USP4-D1D2 over the immobilized Ublinsert in the presence of increasing amounts of Ub. The data could be fitted to a one-site competition binding model, showing that the USP4 insert containing Ubl competes with Ub for binding to the catalytic domain, USP4-D1D2. Additional experiments, using Isothermal Titration Calorimeter, showed that the Kd values of the constructs D1-Ubl-insert-D2, and USP4-D1D2 for Ub were comparable.
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Data from SPR-based assays indicated that Ub binds to D1-Ubl-insert-D2 with slower off-and on-rates than when binding to USP4-D1D2. The researchers concluded that the insert prevents both rapid binding and rapid release of the Ub substrate, thus allowing competitive binding. The similarity of the KD values for purified Ubl and Ubl-insert (Fig 5B-D) suggested that the Ubl domain is the functional part of the insert. SPR-based analysis was also used to demonstrate that the Ubl domain could bind to the catalytic domain of other DUBs. Luna-Vargas and co-workers summarized their data in a model in which DUB activity is partially inhibited by the Ubl domain, which binds to the Ub-binding region of USP4, thus preventing Ub substrate binding (Fig 6) .
Explore more
What do you need to get the confidence to take the next step in your research or to submit your next paper for publication? Just imagine what a better understanding of molecular function and activity could do for your research.
Biacore systems can provide key data in real-time to discriminate crucial differences in affinity, even for interactions where challenging targets are involved.
Biacore systems are designed to help you to generate decisive, information-rich data, that will help answer key questions concerning the nature of binding. 
Importance of outstanding SPR sensitivity for reliable binding results
Full characterization of antigen-antibody interactions is of great importance when assessing the suitability of antibodies as therapeutic or diagnostic tools. Ranking of strong binders can be complicated by avidity effects, and the dissociation rate will appear slower than in reality. To clearly differentiate strong-binding antibodies in terms of dissociation rates, it is necessary to use low levels of immobilized binding partner to obtain clean, avidity-free interaction studies. Obtaining accurate data from the low immobilization levels requires a highly sensitive SPR sensor for the analysis. Sensitivity and low baseline noise are equally important to reliably detect and profile interactions involving very small compounds or targets with low activity levels. High sensitivity with low noise enables resolution of sensorgrams at sub-resonance unit levels, exemplified in Figure 3 . 
Conclusion
Understanding the nature of interactions between molecules is fundamentally important for increased understanding of biological processes. The sensitivity and performance of Biacore systems provide high-quality molecular interactions data in a range of fields, including research, drug discovery, development, and quality control.
This information provides an extra dimension which can be crucial in supporting hit-to-lead development (Fig 2) .
Kinetic properties play an important role in pharmacokinetics for drug development. A compound that shows rapid binding will have a quick effect, but if dissociation is also fast the effect will be short-lived. On the other hand, a compound with slower binding kinetics might need more time to reach full effect but will not need to be given as often. 
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Conclusion
Kinetic properties play an important role in pharmacokinetics for drug development. A compound that shows rapid binding will have a quick effect, but if dissociation is also fast the effect will be short-lived. On the other hand, a compound with slower binding kinetics might need more time to reach full effect but will not need to be given as often.
